

# Jens J Holst Dmsci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/886838/publications.pdf>

Version: 2024-02-01

1,102  
papers

74,016  
citations

464

130  
h-index

1627

215  
g-index

1117  
all docs

1117  
docs citations

1117  
times ranked

39724  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of 6 weeks of very low-volume high-intensity interval training on oral glucose-stimulated incretin hormone response. <i>European Journal of Sport Science</i> , 2022, 22, 381-389.	1.4	4
2	Entero-Pancreatic Hormone Secretion, Gastric Emptying, and Glucose Absorption After Frequently Sampled Meal Tests. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e188-e204.	1.8	4
3	Effects of a Lifestyle Intervention on Bone Turnover in Persons with Type 2 Diabetes: A Post Hoc Analysis of the U-TURN Trial. <i>Medicine and Science in Sports and Exercise</i> , 2022, 54, 38-46.	0.2	4
4	Actions of glucagon-like peptide-1 receptor ligands in the gut. <i>British Journal of Pharmacology</i> , 2022, 179, 727-742.	2.7	22
5	Gastrointestinal Hormones and $\beta^2$ -Cell Function After Gastric Bypass and Sleeve Gastrectomy: A Randomized Controlled Trial (Oseberg). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e756-e766.	1.8	14
6	Glucose-dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, double-blind, placebo-controlled, crossover clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 142-147.	2.2	4
7	Fortifying a meal with oyster mushroom powder beneficially affects postprandial glucagon-like peptide-1, non-esterified free fatty acids and hunger sensation in adults with impaired glucose tolerance: a double-blind randomized controlled crossover trial. <i>European Journal of Nutrition</i> , 2022, 61, 687-701.	1.8	10
8	Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (<sc>RENALIS</sc>): A predefined substudy of a randomized, double-blind trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 115-124.	2.2	7
9	Colonic Lactulose Fermentation Has No Impact on Glucagon-like Peptide-1 and Peptide-YY Secretion in Healthy Young Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 77-87.	1.8	6
10	Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 221-227.	2.2	5
11	Glucagon Clearance Is Preserved in Type 2 Diabetes. <i>Diabetes</i> , 2022, 71, 73-82.	0.3	6
12	The incretin/glucagon system as a target for pharmacotherapy of obesity. <i>Obesity Reviews</i> , 2022, 23, .	3.1	26
13	Expression Profile of the GLP-1 Receptor in the Gastrointestinal Tract and Pancreas in Adult Female Mice. <i>Endocrinology</i> , 2022, 163, .	1.4	8
14	Peptides in the regulation of glucagon secretion. <i>Peptides</i> , 2022, 148, 170683.	1.2	16
15	Molecular and in vivo phenotyping of missense variants of the human glucagon receptor. <i>Journal of Biological Chemistry</i> , 2022, 298, 101413.	1.6	8
16	GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment. <i>Pharmacological Research</i> , 2022, 176, 106058.	3.1	13
17	The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetes. <i>European Journal of Endocrinology</i> , 2022, 186, 207-221.	1.9	3
18	Glucagon-like peptide-1: Are its roles as endogenous hormone and therapeutic wizard congruent?. <i>Journal of Internal Medicine</i> , 2022, 291, 557-573.	2.7	7

#	ARTICLE	IF	CITATIONS
19	Gastric Aspiration Improves Postprandial Glucose Tolerance Without Causing a Compensatory Increase in Appetite and Food Intake. <i>Obesity Surgery</i> , 2022, 32, 1385-1390.	1.1	0
20	Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial. <i>Diabetologia</i> , 2022, 65, 506-517.	2.9	37
21	Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 806-815.	2.2	0
22	The Role of D-allulose and Erythritol on the Activity of the Gut Sweet Taste Receptor and Gastrointestinal Satiety Hormone Release in Humans: A Randomized, Controlled Trial. <i>Journal of Nutrition</i> , 2022, 152, 1228-1238.	1.3	8
23	Atlas of exercise metabolism reveals time-dependent signatures of metabolic homeostasis. <i>Cell Metabolism</i> , 2022, 34, 329-345.e8.	7.2	86
24	Comparative analysis of oral and intraperitoneal glucose tolerance tests in mice. <i>Molecular Metabolism</i> , 2022, 57, 101440.	3.0	25
25	Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid Malabsorption. , 2022, 1, 299-312.		5
26	Hyperglucagonemia in Pediatric Adiposity Associates With Cardiometabolic Risk Factors but Not Hyperglycemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1569-1576.	1.8	7
27	THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin â€“ physiology and pharmacology. <i>European Journal of Endocrinology</i> , 2022, 186, R93-R111.	1.9	4
28	Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. <i>Diabetes Care</i> , 2022, 45, 1476-1481.	4.3	6
29	Opposing roles of the entero-pancreatic hormone urocortin-3 in glucose metabolism in rats. <i>Diabetologia</i> , 2022, 65, 1018-1031.	2.9	2
30	LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men. <i>Cell Reports Medicine</i> , 2022, 3, 100582.	3.3	21
31	Measurement of plasma glucagon in humans: A shift in the performance of a current commercially available radioimmunoassay kit. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1182-1184.	2.2	8
32	Long-term outcomes of dietary carbohydrate restriction for HbA1c reduction in type 2 diabetes mellitus are needed. Reply to Kang J and Ma E [letter]. <i>Diabetologia</i> , 2022, , 1.	2.9	0
33	GLP-1 â€“ Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy. <i>Current Opinion in Pharmacology</i> , 2022, 63, 102189.	1.7	10
34	Fiber mixture-specific effect on distal colonic fermentation and metabolic health in lean but not in prediabetic men. <i>Gut Microbes</i> , 2022, 14, 2009297.	4.3	15
35	On measurements of glucagon secretion in healthy, obese, and Roux-en-Y gastric bypass operated individuals using sandwich ELISA. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2022, 82, 75-83.	0.6	7
36	Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial. <i>Human Reproduction</i> , 2022, 37, 1414-1422.	0.4	34

#	ARTICLE	IF	CITATIONS
37	Extreme duration exercise affects old and younger men differently. <i>Acta Physiologica</i> , 2022, 235, e13816.	1.8	14
38	Early effects of Roux-en-Y gastric bypass on dietary fatty acid absorption and metabolism in people with obesity and normal glucose tolerance. <i>International Journal of Obesity</i> , 2022, 46, 1359-1365.	1.6	0
39	Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy. <i>Frontiers in Nutrition</i> , 2022, 9, 889710.	1.6	4
40	Glucose- and Bile Acid-Stimulated Secretion of Gut Hormones in the Isolated Perfused Intestine Is Not Impaired in Diet-Induced Obese Mice. <i>Frontiers in Endocrinology</i> , 2022, 13, .	1.5	5
41	Impact of Polymorphism in the Î²2-Receptor Gene on Metabolic Responses to Repeated Hypoglycemia in Healthy Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3194-e3205.	1.8	1
42	Acute concomitant glucoseâ€dependent insulinotropic polypeptide receptor antagonism during glucagonâ€like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1882-1887.	2.2	5
43	The Sensory Mechanisms of Nutrient-Induced GLP-1 Secretion. <i>Metabolites</i> , 2022, 12, 420.	1.3	16
44	Nâ€terminal alterations turn the gut hormone GLPâ€2 into an antagonist with gradual loss of GLPâ€2 receptor selectivity towards more GLPâ€1 receptor interaction. <i>British Journal of Pharmacology</i> , 2022, 179, 4473-4485.	2.7	5
45	Studies in Rats of Combined Muscle and Liver Perfusion and of Muscle Extract Indicate That Contractions Release a Muscle Hormone Directly Enhancing Hepatic Glycogenolysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 837.	1.1	0
46	Discovery of the GI Effects of GLP-1: An Historical Perspective. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2716-2720.	1.1	5
47	Weight-loss induced by carbohydrate restriction does not negatively affect health-related quality of life and cognition in people with type 2 diabetes: A randomised controlled trial. <i>Clinical Nutrition</i> , 2022, , .	2.3	5
48	The Liverâ€Î±-Cell Axis in Health and in Disease. <i>Diabetes</i> , 2022, 71, 1852-1861.	0.3	26
49	Glucoseâ€dependent insulinotropic polypeptide receptor antagonist treatment causes a reduction in weight gain in ovariectomised high fat dietâ€fed mice. <i>British Journal of Pharmacology</i> , 2022, 179, 4486-4499.	2.7	7
50	Glucagonâ€like peptideâ€1 effect on Î²â€cell function varies according to diabetes remission status after Rouxâ€enâ€Y gastric bypass. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2081-2089.	2.2	3
51	Arginine-induced glucagon secretion and glucagon-induced enhancement of amino acid catabolism are not influenced by ambient glucose levels in mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2022, 323, E207-E214.	1.8	6
52	The effect of curcumin on hepatic fat content in individuals with obesity. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2192-2202.	2.2	8
53	No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled <sc>PREâ€D</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 530-539.	2.2	9
54	Cerebral effects of glucagonâ€like peptideâ€1 receptor blockade before and after <sc>Rouxâ€enâ€Y</sc> gastric bypass surgery in obese women: A proofâ€ofâ€concept restingâ€state <sc>functional MRI</sc> study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 415-424.	2.2	8

#	ARTICLE	IF	CITATIONS
55	Paracrine regulation of somatostatin secretion by insulin and glucagon in mouse pancreatic islets. <i>Diabetologia</i> , 2021, 64, 142-151.	2.9	28
56	The liver's "alpha cell axis" associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels. <i>Diabetologia</i> , 2021, 64, 512-520.	2.9	26
57	Effects of a whey protein pre-meal on bone turnover in participants with and without type 2 diabetes: A post hoc analysis of a randomised, controlled, crossover trial. <i>Diabetic Medicine</i> , 2021, 38, e14471.	1.2	1
58	Glucose-Dependent Insulinotropic Peptide in the High-Normal Range Is Associated With Increased Carotid Intima-Media Thickness. <i>Diabetes Care</i> , 2021, 44, 224-230.	4.3	20
59	Pharmacokinetics of exogenous GIP(1-42) in C57Bl/6 mice; Extremely rapid degradation but marked variation between available assays. <i>Peptides</i> , 2021, 136, 170457.	1.2	2
60	The effect of preceding glucose decline rate on low-dose glucagon efficacy in individuals with type 1 diabetes: A randomized crossover trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1057-1062.	2.2	0
61	Effects of carbohydrate restriction on postprandial glucose metabolism, $\beta$ -cell function, gut hormone secretion, and satiety in patients with Type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 320, E7-E18.	1.8	17
62	Preserved postprandial suppression of bone turnover markers, despite increased fasting levels, in postmenopausal women. <i>Bone</i> , 2021, 143, 115612.	1.4	2
63	Effects of whey protein and dietary fiber intake on insulin sensitivity, body composition, energy expenditure, blood pressure, and appetite in subjects with abdominal obesity. <i>European Journal of Clinical Nutrition</i> , 2021, 75, 611-619.	1.3	21
64	Dose-dependent efficacy of the glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist GIP(3-30)NH <sub>2</sub> on GIP actions in humans. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 68-74.	2.2	14
65	The Renal Extraction and the Natriuretic Action of GLP-1 in Humans Depend on Interaction With the GLP-1 Receptor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e11-e19.	1.8	12
66	Parenteral nutrition impairs plasma bile acid and gut hormone responses to mixed meal testing in lean healthy men. <i>Clinical Nutrition</i> , 2021, 40, 1013-1021.	2.3	9
67	Can Metabolite and Hormone Profiles Provide a Rationale for Choosing Between Bariatric Procedures?. <i>Obesity Surgery</i> , 2021, 31, 2174-2179.	1.1	3
68	Intestinal Adaptation upon Chemotherapy-Induced Intestinal Injury in Mice Depends on GLP-2 Receptor Activation. <i>Biomedicines</i> , 2021, 9, 46.	1.4	10
69	Effect of the Natural Sweetener Xylitol on Gut Hormone Secretion and Gastric Emptying in Humans: A Pilot Dose-Ranging Study. <i>Nutrients</i> , 2021, 13, 174.	1.7	17
70	Genome-wide association study of circulating levels of glucagon during an oral glucose tolerance test. <i>BMC Medical Genomics</i> , 2021, 14, 3.	0.7	3
71	What is Diabetes Remission?. <i>Diabetes Therapy</i> , 2021, 12, 641-646.	1.2	6
72	Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans. <i>Endocrine Connections</i> , 2021, 10, 205-213.	0.8	4

#	ARTICLE	IF	CITATIONS
73	Gastric emptying of solutions containing the natural sweetener erythritol and effects on gut hormone secretion in humans: A pilot dose-ranging study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1311-1321.	2.2	19
74	Fasting Plasma GLP-1 Is Associated With Overweight/Obesity and Cardiometabolic Risk Factors in Children and Adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1718-1727.	1.8	22
75	Dietary Fiber Is Essential to Maintain Intestinal Size, L-Cell Secretion, and Intestinal Integrity in Mice. <i>Frontiers in Endocrinology</i> , 2021, 12, 640602.	1.5	9
76	Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects. <i>Diabetes</i> , 2021, 70, 1347-1356.	0.3	9
77	Factors Associated with Favorable Changes in Food Preferences After Bariatric Surgery. <i>Obesity Surgery</i> , 2021, 31, 3514-3524.	1.1	13
78	The Role of Incretins on Insulin Function and Glucose Homeostasis. <i>Endocrinology</i> , 2021, 162, .	1.4	43
79	Resistant Starch Combined with Whey Protein Increases Postprandial Metabolism and Lowers Glucose and Insulin Responses in Healthy Adult Men. <i>Foods</i> , 2021, 10, 537.	1.9	3
80	The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. <i>European Journal of Endocrinology</i> , 2021, 184, 383-394.	1.9	15
81	In patients with controlled acromegaly, indices of glucose homeostasis correlate with IGF-1 levels rather than with type of treatment. <i>Clinical Endocrinology</i> , 2021, 95, 65-73.	1.2	2
82	Î²-Lactoglobulin Is Insulinotropic Compared with Casein and Whey Protein Ingestion during Catabolic Conditions in Men in a Double-Blinded Randomized Crossover Trial. <i>Journal of Nutrition</i> , 2021, 151, 1462-1472.	1.3	4
83	Differential effects of bile acids on the postprandial secretion of gut hormones: a randomized crossover study. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 320, E671-E679.	1.8	8
84	GIP receptor deletion in mice confers resistance to high-fat diet-induced obesity via alterations in energy expenditure and adipose tissue lipid metabolism. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 320, E835-E845.	1.8	17
85	GLP-1 and Intestinal Diseases. <i>Biomedicines</i> , 2021, 9, 383.	1.4	20
86	Acute ketosis inhibits appetite and decreases plasma concentrations of acyl ghrelin in healthy young men. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1834-1842.	2.2	13
87	Voices: Insulin and beyond. <i>Cell Metabolism</i> , 2021, 33, 692-699.	7.2	3
88	Exploring the GLP-1/GLP-1R axis in porcine pancreas and gastrointestinal tract in vivo by ex vivo autoradiography. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002083.	1.2	2
89	Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000604.	1.1	8
90	Follistatin secretion is enhanced by protein, but not glucose or fat ingestion, in obese persons independently of previous gastric bypass surgery. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G753-G758.	1.6	1

#	ARTICLE	IF	CITATIONS
91	Effects of a Self-Prepared Carbohydrate-Reduced High-Protein Diet on Cardiovascular Disease Risk Markers in Patients with Type 2 Diabetes. <i>Nutrients</i> , 2021, 13, 1694.	1.7	6
92	Intestinal Growth in Glucagon Receptor Knockout Mice Is Not Associated With the Formation of AOM/DSS-Induced Tumors. <i>Frontiers in Endocrinology</i> , 2021, 12, 695145.	1.5	2
93	Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab084.	0.1	18
94	Amino acids differ in their capacity to stimulate GLP-1 release from the perfused rat small intestine and stimulate secretion by different sensing mechanisms. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 320, E874-E885.	1.8	25
95	What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?. <i>Cell Reports Medicine</i> , 2021, 2, 100284.	3.3	4
96	Do sodium-glucose co-transporter-2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2009-2019.	2.2	3
97	Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass. <i>Frontiers in Endocrinology</i> , 2021, 12, 681116.	1.5	7
98	Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. <i>New England Journal of Medicine</i> , 2021, 384, 1719-1730.	13.9	171
99	Pancreatic polypeptide: A potential biomarker of glucose-dependent insulinotropic polypeptide receptor activation in vivo. <i>Diabetic Medicine</i> , 2021, 38, e14592.	1.2	1
100	Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls. <i>European Journal of Endocrinology</i> , 2021, 185, 343-353.	1.9	12
101	Effect of Fecal Microbiota Transplantation Combined With Mediterranean Diet on Insulin Sensitivity in Subjects With Metabolic Syndrome. <i>Frontiers in Microbiology</i> , 2021, 12, 662159.	1.5	22
102	Body weight and metabolic risk factors in patients with type 2 diabetes on a self-selected high-protein low-carbohydrate diet. <i>European Journal of Nutrition</i> , 2021, 60, 4473-4482.	1.8	5
103	Age-dependent transition from islet insulin hypersecretion to hyposecretion in mice with the long QT-syndrome loss-of-function mutation <i>Kcnq1-A340V</i> . <i>Scientific Reports</i> , 2021, 11, 12253.	1.6	10
104	What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?. <i>Frontiers in Endocrinology</i> , 2021, 12, 694284.	1.5	22
105	The role of GLP-1 in postprandial glucose metabolism after bariatric surgery: a narrative review of human GLP-1 receptor antagonist studies. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, 1383-1391.	1.0	19
106	Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults. <i>European Journal of Endocrinology</i> , 2021, 185, 23-32.	1.9	2
107	Effects of endogenous GIP in patients with type 2 diabetes. <i>European Journal of Endocrinology</i> , 2021, 185, 33-45.	1.9	21
108	The Effect of Melatonin on Incretin Hormones: Results From Experimental and Randomized Clinical Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e5109-e5123.	1.8	1

#	ARTICLE	IF	CITATIONS
109	The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial. <i>Diabetologia</i> , 2021, 64, 2425-2431.	2.9	4
110	Neurotensin secretion after Roux-en-Y gastric bypass, sleeve gastrectomy, and truncal vagotomy with pyloroplasty. <i>Neurogastroenterology and Motility</i> , 2021, , e14210.	1.6	2
111	L-Cell Expression of Melanocortin-4-Receptor Is Marginal in Most of the Small Intestine in Mice and Humans and Direct Stimulation of Small Intestinal Melanocortin-4-Receptors in Mice and Rats Does Not Affect GLP-1 Secretion. <i>Frontiers in Endocrinology</i> , 2021, 12, 690387.	1.5	2
112	Metformin Stimulates Intestinal Glycolysis and Lactate Release: A single-Dose Study of Metformin in Patients With Intrahepatic Portosystemic Stent. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1329-1336.	2.3	11
113	Effects of prebiotics on postprandial GLP-1, GLP-2 and glucose regulation in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled crossover trial. <i>Diabetic Medicine</i> , 2021, 38, e14657.	1.2	8
114	The liver-alpha-cell axis after a mixed meal and during weight loss in type 2 diabetes. <i>Endocrine Connections</i> , 2021, 10, 1101-1110.	0.8	5
115	Role of fasting duration and weekday in incretin and glucose regulation. <i>Endocrine Connections</i> , 2021, 10, X2-X3.	0.8	0
116	Plasma GDF15 levels are similar between subjects after bariatric surgery and matched controls and are unaffected by meals. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 321, E443-E452.	1.8	5
117	Associations between ghrelin and leptin and neural food cue reactivity in a fasted and sated state. <i>NeuroImage</i> , 2021, 240, 118374.	2.1	18
118	Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study. <i>Bone</i> , 2021, 152, 116065.	1.4	8
119	Counterregulatory responses to postprandial hypoglycemia after Roux-en-Y gastric bypass. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, 55-63.	1.0	9
120	Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R-dependent manner. <i>JCI Insight</i> , 2021, 6, .	2.3	14
121	GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in Rats. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 296-313.	2.5	24
122	Using a Reporter Mouse to Map Known and Novel Sites of GLP-1 Receptor Expression in Peripheral Tissues of Male Mice. <i>Endocrinology</i> , 2021, 162, .	1.4	33
123	Salivary ghrelin response to drinks varying in protein content and quantity and association with energy intake and appetite. <i>Physiology and Behavior</i> , 2021, 242, 113622.	1.0	0
124	Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture. <i>Diabetes</i> , 2021, 70, 2468-2475.	0.3	14
125	Congenital Glucagon-like Peptide-1 Deficiency in the Pathogenesis of Protracted Diarrhea in Mitchell-Riley Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1084-e1090.	1.8	7
126	Novel agonist- and antagonist-based radioligands for the GLP-2 receptor - useful tools for studies of basic GLP-2R pharmacology. <i>British Journal of Pharmacology</i> , 2021, , .	2.7	5



#	ARTICLE	IF	CITATIONS
127	Combinatorial, additive and dose-dependent drug-microbiome associations. <i>Nature</i> , 2021, 600, 500-505.	13.7	102
128	Glucagon-Like Peptide-1 Is Associated With Systemic Inflammation in Pediatric Patients Treated With Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 793588.	2.2	3
129	Intestinal sensing and handling of dietary lipids in gastric bypass-operated patients and matched controls. <i>American Journal of Clinical Nutrition</i> , 2020, 111, 28-41.	2.2	7
130	Ghrelin Does Not Directly Stimulate Secretion of Glucagon-like Peptide-1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 266-275.	1.8	8
131	Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e564-e574.	1.8	3
132	Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 117-125.	1.3	7
133	A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals. <i>Obesity Surgery</i> , 2020, 30, 1605-1610.	1.1	10
134	No evidence of tachyphylaxis for insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects. <i>Peptides</i> , 2020, 125, 170176.	1.2	3
135	Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. <i>Peptides</i> , 2020, 125, 170183.	1.2	61
136	Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e502-e510.	1.8	12
137	In vivo positron emission tomography imaging of decreased parasympathetic innervation in the gut of vagotomized patients. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13759.	1.6	7
138	GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH <sub>2</sub> . <i>Bone</i> , 2020, 130, 115079.	1.4	20
139	Recent advances of GIP and future horizons. <i>Peptides</i> , 2020, 125, 170230.	1.2	21
140	Gastric Bypass with Different Biliopancreatic Limb Lengths Results in Similar Post-absorptive Metabolomics Profiles. <i>Obesity Surgery</i> , 2020, 30, 1068-1078.	1.1	5
141	Incretin therapy for diabetes mellitus type 2. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 2-10.	1.2	21
142	Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide-Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2020, 69, 146-157.	0.3	11
143	Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People. <i>Diabetes Care</i> , 2020, 43, 411-417.	4.3	41
144	Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	0.9	3

#	ARTICLE	IF	CITATIONS
145	The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition. <i>Diabetes</i> , 2020, 69, 2619-2629.	0.3	11
146	Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes. <i>Nutrients</i> , 2020, 12, 2928.	1.7	2
147	Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis. <i>Molecular Metabolism</i> , 2020, 42, 101080.	3.0	66
148	One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 3213.	1.0	14
149	Normal insulin sensitivity, glucose tolerance, gut incretin and pancreatic hormone responses in adults with atopic dermatitis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2161-2169.	2.2	1
150	Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA). <i>Diabetes Care</i> , 2020, 43, 2025-2033.	4.3	22
151	Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00130.	1.0	2
152	Oral <i>D/L</i> -3-Hydroxybutyrate Stimulates Cholecystokinin and Insulin Secretion and Slows Gastric Emptying in Healthy Males. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3597-e3605.	1.8	18
153	The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. <i>Bone</i> , 2020, 140, 115553.	1.4	25
154	Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa097.	0.1	12
155	The clinical effects of a carbohydrate-reduced high-protein diet on glycaemic variability in metformin-treated patients with type 2 diabetes mellitus: A randomised controlled study. <i>Clinical Nutrition ESPEN</i> , 2020, 39, 46-52.	0.5	8
156	Relationship between biochemical and symptomatic hypoglycemia after RYGB. Responses to a mixed meal test: a case-control study. <i>Surgery for Obesity and Related Diseases</i> , 2020, 16, 1179-1185.	1.0	6
157	Increased oral sodium chloride intake in humans amplifies selectively postprandial GLP-1 but not GIP, CCK, and gastrin in plasma. <i>Physiological Reports</i> , 2020, 8, e14519.	0.7	6
158	Endocrine and Metabolic Insights from Pancreatic Surgery. <i>Trends in Endocrinology and Metabolism</i> , 2020, 31, 760-772.	3.1	18
159	Protocol for a single-centre, parallel-group, randomised, controlled, superiority trial on the effects of time-restricted eating on body weight, behaviour and metabolism in individuals at high risk of type 2 diabetes: the REstricted Eating Time (RESET) study. <i>BMJ Open</i> , 2020, 10, e037166.	0.8	13
160	Nonalcoholic Fatty Liver Disease Impairs the Liver's Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis. <i>Hepatology Communications</i> , 2020, 4, 1610-1623.	2.0	22
161	Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial. <i>Diabetes Care</i> , 2020, 43, 2889-2893.	4.3	10
162	Effects of an intensive lifestyle intervention on the underlying mechanisms of improved glycaemic control in individuals with type 2 diabetes: a secondary analysis of a randomised clinical trial. <i>Diabetologia</i> , 2020, 63, 2410-2422.	2.9	16

#	ARTICLE	IF	CITATIONS
163	An atlas of O-linked glycosylation on peptide hormones reveals diverse biological roles. <i>Nature Communications</i> , 2020, 11, 4033.	5.8	46
164	A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia. <i>Frontiers in Endocrinology</i> , 2020, 11, 608248.	1.5	10
165	Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches. <i>Biology</i> , 2020, 9, 473.	1.3	35
166	Appetite Control across the Lifecourse: The Acute Impact of Breakfast Drink Quantity and Protein Content. The Full4Health Project. <i>Nutrients</i> , 2020, 12, 3710.	1.7	7
167	High-Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta-Adrenoceptor Blockade: A Randomized Clinical Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e016828.	1.6	15
168	Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. <i>Nature</i> , 2020, 581, 310-315.	13.7	283
169	Bilio-enteric flow and plasma concentrations of bile acids after gastric bypass and sleeve gastrectomy. <i>International Journal of Obesity</i> , 2020, 44, 1872-1883.	1.6	13
170	Effects of a highly controlled carbohydrate-reduced high-protein diet on markers of oxidatively generated nucleic acid modifications and inflammation in weight stable participants with type 2 diabetes; a randomized controlled trial. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2020, 80, 401-407.	0.6	10
171	The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial. <i>Diabetologia</i> , 2020, 63, 1285-1298.	2.9	11
172	GLP-1-induced renal vasodilation in rodents depends exclusively on the known GLP-1 receptor and is lost in prehypertensive rats. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, F1409-F1417.	1.3	16
173	GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2710-e2716.	1.8	97
174	Different Malabsorptive Obesity Surgery Interventions Result in Distinct Postprandial Amino Acid Metabolomic Signatures. <i>Obesity Surgery</i> , 2020, 30, 4019-4028.	1.1	4
175	No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1837-1846.	2.2	4
176	GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1 $\alpha$ Mutation Carriers. <i>Diabetes</i> , 2020, 69, 1989-2002.	0.3	14
177	Glucagon receptor signaling is not required for N-carbamoyl glutamate- and L-citrulline-induced ureagenesis in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G912-G927.	1.6	4
178	The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 318, E956-E964.	1.8	13
179	In the rat pancreas, somatostatin tonically inhibits glucagon secretion and is required for glucose-induced inhibition of glucagon secretion. <i>Acta Physiologica</i> , 2020, 229, e13464.	1.8	31
180	Enteroendocrine K Cells Exert Complementary Effects to Control Bone Quality and Mass in Mice. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1363-1374.	3.1	12

#	ARTICLE	IF	CITATIONS
181	Acute Effects of Three Different Meal Patterns on Postprandial Metabolism in Older Individuals with a Risk Phenotype for Cardiometabolic Diseases: A Randomized Controlled Crossover Trial. <i>Molecular Nutrition and Food Research</i> , 2020, 64, e1901035.	1.5	13
182	Gain-of-function mutation in the voltage-gated potassium channel gene <i>KCNQ1</i> and glucose-stimulated hypoinsulinemia - case report. <i>BMC Endocrine Disorders</i> , 2020, 20, 38.	0.9	6
183	Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 313-324.	5.5	39
184	Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent. <i>Neurochemistry International</i> , 2020, 138, 104772.	1.9	11
185	Secretin release after Roux-en-Y gastric bypass reveals a population of glucose-sensitive S cells in distal small intestine. <i>International Journal of Obesity</i> , 2020, 44, 1859-1871.	1.6	25
186	Oxyntomodulin and Glicentin May Predict the Effect of Bariatric Surgery on Food Preferences and Weight Loss. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1064-e1074.	1.8	42
187	Nutrient Restriction has Limited Short-Term Effects on Gut, Immunity, and Brain Development in Preterm Pigs. <i>Journal of Nutrition</i> , 2020, 150, 1196-1207.	1.3	10
188	Responses of gut and pancreatic hormones, bile acids, and fibroblast growth factor-21 differ to glucose, protein, and fat ingestion after gastric bypass surgery. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G661-G672.	1.6	27
189	Glucagon-Like Peptide 1 and Atrial Natriuretic Peptide in a Female Mouse Model of Obstructive Pulmonary Disease. <i>Journal of the Endocrine Society</i> , 2020, 4, bvz034.	0.1	11
190	GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e725-e738.	1.8	37
191	Consumption of nutrients and insulin resistance suppress markers of bone turnover in subjects with abdominal obesity. <i>Bone</i> , 2020, 133, 115230.	1.4	23
192	No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 588-596.	4.3	38
193	Effect of wheat bran derived prebiotic supplementation on gastrointestinal transit, gut microbiota, and metabolic health: a randomized controlled trial in healthy adults with a slow gut transit. <i>Gut Microbes</i> , 2020, 12, 1704141.	4.3	46
194	Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis. <i>Diabetes</i> , 2020, 69, 1090-1099.	0.3	50
195	Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study. <i>Diabetologia</i> , 2020, 63, 1043-1054.	2.9	18
196	Evidence for Relationship Between Early Dumping and Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass. <i>Obesity Surgery</i> , 2020, 30, 1038-1045.	1.1	10
197	CCK $\epsilon$ 1 and CCK $\epsilon$ 2 receptor agonism do not stimulate GLP $\epsilon$ 1 and neurotensin secretion in the isolated perfused rat small intestine or GLP $\epsilon$ 1 and PYY secretion in the rat colon. <i>Physiological Reports</i> , 2020, 8, e14352.	0.7	5
198	Alanine, arginine, cysteine, and proline, but not glutamine, are substrates for, and acute mediators of, the liver- $\beta$ -cell axis in female mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 318, E920-E929.	1.8	32

#	ARTICLE	IF	CITATIONS
199	Proglucagon peptide secretion profiles in type 2 diabetes before and after bariatric surgery: 1-year prospective study. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001076.	1.2	18
200	Predictors of weight loss after bariatric surgery—a cross-disciplinary approach combining physiological, social, and psychological measures. <i>International Journal of Obesity</i> , 2020, 44, 2291-2302.	1.6	26
201	Pharmacological activation of TGR5 promotes intestinal growth via a GLP-2-dependent pathway in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G980-G987.	1.6	11
202	Changes in the Homeostatic Appetite System After Weight Loss Reflect a Normalization Toward a Lower Body Weight. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2538-e2546.	1.8	22
203	The Antiresorptive Effect of GIP, But Not GLP-2, Is Preserved in Patients With Hypoparathyroidism—A Randomized Crossover Study. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1448-1458.	3.1	17
204	GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report. <i>Cell Reports Medicine</i> , 2020, 1, 100006.	3.3	22
205	Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. <i>JCI Insight</i> , 2020, 5, .	2.3	177
206	Role of fasting duration and weekday in incretin and glucose regulation. <i>Endocrine Connections</i> , 2020, 9, 279-288.	0.8	5
207	Secretion of parathyroid hormone may be coupled to insulin secretion in humans. <i>Endocrine Connections</i> , 2020, 9, 747-754.	0.8	6
208	89-LB: The Effect of GIP on Plasma Glucose in a Setting of Prandial Insulin Overdose and Physical Activity after Meal Intake in Patients with Type 1 Diabetes. <i>Diabetes</i> , 2020, 69, .	0.3	3
209	Hepatic Bile Acid Reuptake in the Rat Depends on Bile Acid Conjugation but Not on Agonistic Properties towards FXR and TGR5. <i>Molecules</i> , 2020, 25, 2371.	1.7	0
210	No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect. <i>Endocrine Connections</i> , 2020, 9, 1221-1232.	0.8	2
211	Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00257.	1.3	8
212	Abscisic acid stimulates the release of insulin and of GLP-1 in the rat perfused pancreas and intestine. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3102.	1.7	5
213	Gut hormone release after gastric bypass depends on the length of the biliopancreatic limb. <i>International Journal of Obesity</i> , 2019, 43, 1009-1018.	1.6	27
214	Investigating Intestinal Glucagon After Roux-en-Y Gastric Bypass Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6403-6416.	1.8	34
215	Sacubitril/Valsartan Augments Postprandial Plasma Concentrations of Active GLP-1 When Combined With Sitagliptin in Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3868-3876.	1.8	18
216	The imprinted gene Delta like non-canonical notch ligand 1 (Dlk1) associates with obesity and triggers insulin resistance through inhibition of skeletal muscle glucose uptake. <i>EBioMedicine</i> , 2019, 46, 368-380.	2.7	23

#	ARTICLE	IF	CITATIONS
217	GLP-1 secretion in acute ischemic stroke: association with functional outcome and comparison with healthy individuals. <i>Cardiovascular Diabetology</i> , 2019, 18, 91.	2.7	3
218	Glucagon Receptor Signaling and Glucagon Resistance. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3314.	1.8	113
219	A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial. <i>Diabetologia</i> , 2019, 62, 2066-2078.	2.9	98
220	The Liver- $\alpha$ -Cell Axis and Type 2 Diabetes. <i>Endocrine Reviews</i> , 2019, 40, 1353-1366.	8.9	110
221	Sustained Improvements in Glucose Metabolism Late After Roux-En-Y Gastric Bypass Surgery in Patients with and Without Preoperative Diabetes. <i>Scientific Reports</i> , 2019, 9, 15154.	1.6	6
222	Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5703-5714.	1.8	57
223	Physiology of the Incretin Hormones, $\text{GIP}$ and $\text{GLP-1}$ Regulation of Release and Posttranslational Modifications. , 2019, 9, 1339-1381.		38
224	Glucose homeostasis and the gastrointestinal tract. , 2019, , 3-19.		1
225	Methods and Guidelines for Measurement of Glucagon in Plasma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5416.	1.8	38
226	Effects of Exercise Training and IL-6 Receptor Blockade on Gastric Emptying and GLP-1 Secretion in Obese Humans: Secondary Analyses From a Double Blind Randomized Clinical Trial. <i>Frontiers in Physiology</i> , 2019, 10, 1249.	1.3	12
227	Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats. <i>Frontiers in Endocrinology</i> , 2019, 10, 492.	1.5	21
228	Circulating but not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1 concentrations in humans. <i>Scientific Reports</i> , 2019, 9, 12515.	1.6	200
229	Short-chain fatty acids and regulation of pancreatic endocrine secretion in mice. <i>Islets</i> , 2019, 11, 103-111.	0.9	21
230	Paracrine crosstalk between intestinal L- and D-cells controls secretion of glucagon-like peptide-1 in mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E1081-E1093.	1.8	32
231	Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women. <i>European Journal of Endocrinology</i> , 2019, 180, 417-427.	1.9	24
232	Effects of a High-Protein/Moderate-Carbohydrate Diet on Appetite, Gut Peptides, and Endocannabinoids—A Preview Study. <i>Nutrients</i> , 2019, 11, 2269.	1.7	17
233	Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures. <i>Cardiovascular Diabetology</i> , 2019, 18, 130.	2.7	8
234	Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. <i>Diabetologia</i> , 2019, 62, 665-675.	2.9	81

#	ARTICLE	IF	CITATIONS
235	Gastrointestinal motility in patients with end-stage renal disease on chronic hemodialysis. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13554.	1.6	11
236	Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2581-2592.	1.8	7
237	Augmented GLP-1 Secretion as Seen After Gastric Bypass May Be Obtained by Delaying Carbohydrate Digestion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3233-3244.	1.8	15
238	Pros and cons of Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2019, 14, 243-257.	1.2	5
239	Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease. <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 42.	1.2	10
240	Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?. <i>Lancet, The</i> , 2019, 394, 4-6.	6.3	3
241	Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study. <i>Diabetes Care</i> , 2019, 42, 1446-1453.	4.3	84
242	Fatty Liver Among Adolescent Offspring of Women With Type 1 Diabetes (the EPICOM Study). <i>Diabetes Care</i> , 2019, 42, 1560-1568.	4.3	13
243	Bile Modulates Secretion of Incretins and Insulin: A Study of Human Extrahepatic Cholestasis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2685-2694.	1.8	6
244	Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2142-2151.	2.2	38
245	GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men. <i>Bone</i> , 2019, 125, 178-185.	1.4	45
246	Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. <i>Frontiers in Endocrinology</i> , 2019, 10, 242.	1.5	5
247	Extracellular Fluid Volume Expansion Uncovers a Natriuretic Action of GLP-1: A Functional GLP-1-Renal Axis in Man. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2509-2519.	1.8	29
248	Peptide-mediated glucagon-like peptide-1 secretion depends on intestinal absorption and activation of basolaterally located Calcium-Sensing Receptors. <i>Physiological Reports</i> , 2019, 7, e14056.	0.7	36
249	The incretin system in healthy humans: The role of GIP and GLP-1. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, 46-55.	1.5	127
250	Postprandial Nutrient Handling and Gastrointestinal Hormone Secretion After Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy. <i>Gastroenterology</i> , 2019, 156, 1627-1641.e1.	0.6	99
251	No direct effect of SGLT2 activity on glucagon secretion. <i>Diabetologia</i> , 2019, 62, 1011-1023.	2.9	58
252	Bariatric surgery— which procedure is the optimal choice?. <i>Lancet, The</i> , 2019, 393, 1263-1264.	6.3	10

#	ARTICLE	IF	CITATIONS
253	Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. <i>Molecular Systems Biology</i> , 2019, 15, e8793.	3.2	176
254	Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2953-2960.	1.8	41
255	Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment. <i>Frontiers in Endocrinology</i> , 2019, 10, 75.	1.5	70
256	Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 354-363.	3.7	52
257	Assessment of Islet Alpha- and Beta-Cell Function. , 2019, , 37-74.		1
258	Plasma FGF-19 Levels are Increased in Patients with Post-Bariatric Hypoglycemia. <i>Obesity Surgery</i> , 2019, 29, 2092-2099.	1.1	32
259	From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy. <i>Frontiers in Endocrinology</i> , 2019, 10, 260.	1.5	71
260	Differential action of TGR5 agonists on GLP-2 secretion and promotion of intestinal adaptation in a piglet short bowel model. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G641-G652.	1.6	11
261	Glucagon Receptor Signaling and Lipid Metabolism. <i>Frontiers in Physiology</i> , 2019, 10, 413.	1.3	112
262	Glucagon-Like Peptide-1 Is a Marker of Systemic Inflammation in Patients Treated with High-Dose Chemotherapy and Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1085-1091.	2.0	9
263	The effect of DPP-4-protected GLP-1 (7â€“36) on coronary microvascular function in obese adults. <i>IJC Heart and Vasculature</i> , 2019, 22, 139-144.	0.6	5
264	Bile acids drive colonic secretion of glucagon-like-peptide 1 and peptide-YY in rodents. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G574-G584.	1.6	42
265	Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	7
266	Glucose and amino acid metabolism in mice depend mutually on glucagon and insulin receptor signaling. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 316, E660-E673.	1.8	26
267	Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet. <i>BMJ Open</i> , 2019, 9, e031431.	0.8	11
268	A Pilot Study Showing Acute Inhibitory Effect of GLPâ€“1 on the Bone Resorption Marker CTX in Humans. <i>JBMR Plus</i> , 2019, 3, e10209.	1.3	19
269	Gastric Emptying and Distal Gastrectomy Independently Enhance Postprandial Glucagon-Like Peptide-1 Release After a Mixed Meal and Improve Glycemic Control in Subjects Having Undergone Pancreaticoduodenectomy. <i>Pancreas</i> , 2019, 48, 953-957.	0.5	0
270	Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction. <i>International Journal of Cardiology</i> , 2019, 283, 28-34.	0.8	11



#	ARTICLE	IF	CITATIONS
271	Pre-meal and postprandial lipaemia in subjects with the metabolic syndrome: effects of timing and protein quality (randomised crossover trial). <i>British Journal of Nutrition</i> , 2019, 121, 312-321.	1.2	9
272	Effects of active commuting and leisure-time exercise on appetite in individuals with overweight and obesity. <i>Journal of Applied Physiology</i> , 2019, 126, 941-951.	1.2	16
273	Neuromedin U Does Not Act as a Decretin in Rats. <i>Cell Metabolism</i> , 2019, 29, 719-726.e5.	7.2	9
274	The aromatic amino acid sensor GPR142 controls metabolism through balanced regulation of pancreatic and gut hormones. <i>Molecular Metabolism</i> , 2019, 19, 49-64.	3.0	43
275	Preserved glucose response to low-dose glucagon after exercise in insulin-pump-treated individuals with type 1 diabetes: a randomised crossover study. <i>Diabetologia</i> , 2019, 62, 582-592.	2.9	18
276	High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. <i>CNS Spectrums</i> , 2019, 24, 441-452.	0.7	15
277	Mechanisms of action of a carbohydrate-reduced, high-protein diet in reducing the risk of postprandial hypoglycemia after Roux-en-Y gastric bypass surgery. <i>American Journal of Clinical Nutrition</i> , 2019, 110, 296-304.	2.2	22
278	Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. <i>Diabetes</i> , 2019, 68, 906-917.	0.3	118
279	Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys. <i>Psychopharmacology</i> , 2019, 236, 603-611.	1.5	36
280	Energy intake, gastrointestinal transit, and gut hormone release in response to oral triglycerides and fatty acids in men with and without severe obesity. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G332-G337.	1.6	10
281	Biliopancreatic diversion with duodenal switch (BPD-DS) and single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) result in distinct post-prandial hormone profiles. <i>International Journal of Obesity</i> , 2019, 43, 2518-2527.	1.6	27
282	Glucose homeostasis in statin usersâ€”The LIFESTAT study. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3110.	1.7	9
283	Mechanisms Preserving Insulin Action during High Dietary Fat Intake. <i>Cell Metabolism</i> , 2019, 29, 50-63.e4.	7.2	50
284	Gastrointestinal motility, gut hormone secretion, and energy intake after oral loads of free fatty acid or triglyceride in older and middle-aged men. <i>Appetite</i> , 2019, 132, 18-24.	1.8	3
285	Whole grain-rich diet reduces body weight and systemic low-grade inflammation without inducing major changes of the gut microbiome: a randomised cross-over trial. <i>Gut</i> , 2019, 68, 83-93.	6.1	278
286	A pre-meal of whey proteins induces differential effects on glucose and lipid metabolism in subjects with the metabolic syndrome: a randomised cross-over trial. <i>European Journal of Nutrition</i> , 2019, 58, 755-764.	1.8	9
287	GLP-induced vasodilation in human adipose tissue involves capillary recruitment. <i>Endocrine Connections</i> , 2019, 8, 806-813.	0.8	14
288	Gluco-metabolic effects of oral and intravenous alcohol administration in men. <i>Endocrine Connections</i> , 2019, 8, 1372-1382.	0.8	7

#	ARTICLE	IF	CITATIONS
289	Habitual physical activity is associated with lower fasting and greater glucose-induced GLP-1 response in men. <i>Endocrine Connections</i> , 2019, 8, 1607-1617.	0.8	5
290	The diurnal variation of bone formation is attenuated in adult patients with type 2 diabetes. <i>European Journal of Endocrinology</i> , 2019, 181, 221-231.	1.9	12
291	Long-acting glucagon-like peptide-1 receptor agonist status December 2018. <i>Annals of Translational Medicine</i> , 2019, 7, 83-83.	0.7	11
292	1952-P: Glucagon Receptor Antagonism Increases Plasma Amino Acids and Glucagon. <i>Diabetes</i> , 2019, 68, .	0.3	3
293	64-OR: Postprandial Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide in Type 2 Diabetes. <i>Diabetes</i> , 2019, 68, .	0.3	10
294	Glucagon Processing. , 2019, , .		0
295	Effect of Liraglutide Treatment on Jejunostomy Output in Patients With Short Bowel Syndrome: An Open-Label Pilot Study. <i>Journal of Parenteral and Enteral Nutrition</i> , 2018, 42, 112-121.	1.3	48
296	Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1623-1631.	2.2	21
297	Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1937-1943.	2.2	3
298	Treatment with GLP-1 Receptor Agonists. <i>Endocrinology</i> , 2018, , 1-45.	0.1	3
299	Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss. <i>Surgery for Obesity and Related Diseases</i> , 2018, 14, 708-714.	1.0	144
300	A carbohydrate-reduced high-protein diet acutely decreases postprandial and diurnal glucose excursions in type 2 diabetes patients. <i>British Journal of Nutrition</i> , 2018, 119, 910-917.	1.2	39
301	Ghrelin secretion in humans – a role for the vagus nerve?. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13295.	1.6	14
302	Systems Signatures Reveal Unique Remission-path of Type 2 Diabetes Following Roux-en-Y Gastric Bypass Surgery. <i>EBioMedicine</i> , 2018, 28, 234-240.	2.7	5
303	Effects of Preceding Ethanol Intake on Glucose Response to Low-Dose Glucagon in Individuals With Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study. <i>Diabetes Care</i> , 2018, 41, 797-806.	4.3	10
304	Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 288-294.	1.8	64
305	Glucagon-Like Peptide-1 Inhibits Prandial Gastrointestinal Motility Through Myenteric Neuronal Mechanisms in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 575-585.	1.8	32
306	Oxyntomodulin: Actions and role in diabetes. <i>Peptides</i> , 2018, 100, 48-53.	1.2	59

#	ARTICLE	IF	CITATIONS
307	Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents. <i>Peptides</i> , 2018, 100, 173-181.	1.2	56
308	Evidence of a liver- $\alpha$ cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids. <i>Diabetologia</i> , 2018, 61, 671-680.	2.9	76
309	Interleukin-6 Delays Gastric Emptying in Humans with Direct Effects on Glycemic Control. <i>Cell Metabolism</i> , 2018, 27, 1201-1211.e3.	7.2	73
310	The effect of casein, hydrolyzed casein, and whey proteins on urinary and postprandial plasma metabolites in overweight and moderately obese human subjects. <i>Journal of the Science of Food and Agriculture</i> , 2018, 98, 5598-5605.	1.7	10
311	Patient profiling for success after weight loss surgery (GO Bypass study): An interdisciplinary study protocol. <i>Contemporary Clinical Trials Communications</i> , 2018, 10, 121-130.	0.5	16
312	Effects of Smoking Versus Nonsmoking on Postprandial Glucose Metabolism in Heavy Smokers Compared With Nonsmokers. <i>Diabetes Care</i> , 2018, 41, 1260-1267.	4.3	13
313	Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas. <i>Molecular Metabolism</i> , 2018, 11, 84-95.	3.0	135
314	The glucagon like peptide-2 $\alpha$ -axis <sup>TM</sup> : Capacity for production and response following intestinal resection or repair of gastroschisis in infants. <i>Journal of Pediatric Surgery</i> , 2018, 53, 898-904.	0.8	9
315	Effects of a diet rich in arabinoxylan and resistant starch compared with a diet rich in refined carbohydrates on postprandial metabolism and features of the metabolic syndrome. <i>European Journal of Nutrition</i> , 2018, 57, 795-807.	1.8	19
316	Gut: A key player in the pathogenesis of type 2 diabetes?. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 1294-1309.	5.4	26
317	Do we know the true mechanism of action of the DPP-4 inhibitors?. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 34-41.	2.2	89
318	Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 215-218.	2.2	108
319	GIP(3-30)NH <sub>2</sub> is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. <i>Diabetologia</i> , 2018, 61, 413-423.	2.9	66
320	Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, G91-G96.	1.6	61
321	Disruption of glucagon receptor signaling causes hyperaminoacidemia exposing a possible liver- $\alpha$ -cell axis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 314, E93-E103.	1.8	84
322	Enteroendocrine K and L cells in healthy and type 2 diabetic individuals. <i>Diabetologia</i> , 2018, 61, 284-294.	2.9	107
323	Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes - A Simulation Study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 322-330.	1.2	4
324	The bile acid-sequestering resin sevelamer eliminates the acute GLP-1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 362-369.	2.2	33

#	ARTICLE	IF	CITATIONS
325	The acute effects of dietary carbohydrate reduction on postprandial responses of non-esterified fatty acids and triglycerides: a randomized trial. <i>Lipids in Health and Disease</i> , 2018, 17, 295.	1.2	9
326	Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1429-1432.	0.6	17
327	Hyperosmolar Duodenal Saline Infusion Lowers Circulating Ghrelin and Stimulates Intestinal Hormone Release in Young Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4409-4418.	1.8	17
328	Plasma Proteome Profiling Reveals Dynamics of Inflammatory and Lipid Homeostasis Markers after Roux-En-Y Gastric Bypass Surgery. <i>Cell Systems</i> , 2018, 7, 601-612.e3.	2.9	80
329	Comparing olive oil and C4-dietary oil, a prodrug for the GPR119 agonist, 2-oleoyl glycerol, less energy intake of the latter is needed to stimulate incretin hormone secretion in overweight subjects with type 2 diabetes. <i>Nutrition and Diabetes</i> , 2018, 8, 2.	1.5	10
330	Reduced GLP-1 Secretion at 30 Minutes After a 75-g Oral Glucose Load Is Observed in Gestational Diabetes Mellitus: A Prospective Cohort Study. <i>Diabetes</i> , 2018, 67, 2650-2656.	0.3	12
331	Response to Letter to the Editor: "Hemodynamic Effects of Glucagon: A Literature Review". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4480-4481.	1.8	0
332	Hepatic Insulin Clearance in Regulation of Systemic Insulin Concentrations—Role of Carbohydrate and Energy Availability. <i>Diabetes</i> , 2018, 67, 2129-2136.	0.3	74
333	Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects. <i>Metabolic Syndrome and Related Disorders</i> , 2018, 16, 530-536.	0.5	22
334	Treatment with GLP-1 Receptor Agonists. <i>Endocrinology</i> , 2018, , 571-615.	0.1	1
335	Insulin Secretion Depends on Intra-islet Glucagon Signaling. <i>Cell Reports</i> , 2018, 25, 1127-1134.e2.	2.9	233
336	Acute Effects of Dietary Carbohydrate Restriction on Glycemia, Lipemia and Appetite Regulating Hormones in Normal-Weight to Obese Subjects. <i>Nutrients</i> , 2018, 10, 1285.	1.7	12
337	No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course. <i>BMC Endocrine Disorders</i> , 2018, 18, 60.	0.9	4
338	Inhibiting RHOA Signaling in Mice Increases Glucose Tolerance and Numbers of Enteroendocrine and Other Secretory Cells in the Intestine. <i>Gastroenterology</i> , 2018, 155, 1164-1176.e2.	0.6	41
339	Renoprotective effects of dulaglutide in patients with T2DM and CKD. <i>Nature Reviews Nephrology</i> , 2018, 14, 659-660.	4.1	4
340	Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. <i>Cell Metabolism</i> , 2018, 28, 23-32.e3.	7.2	88
341	Endogenous glucagon-like peptide- 1 and 2 are essential for regeneration after acute intestinal injury in mice. <i>PLoS ONE</i> , 2018, 13, e0198046.	1.1	23
342	Comparison of Glycomacropptide with Phenylalanine Free-Synthetic Amino Acids in Test Meals to PKU Patients: No Significant Differences in Biomarkers, Including Plasma Phe Levels. <i>Journal of Nutrition and Metabolism</i> , 2018, 2018, 1-11.	0.7	14

#	ARTICLE	IF	CITATIONS
343	The prebiotic inulin improves substrate metabolism and promotes short-chain fatty acid production in overweight to obese men. <i>Metabolism: Clinical and Experimental</i> , 2018, 87, 25-35.	1.5	152
344	Glucose Tolerance Tests and Osteocalcin Responses in Healthy People. <i>Frontiers in Endocrinology</i> , 2018, 9, 356.	1.5	9
345	The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, G53-G65.	1.6	235
346	Older Subjects With $\beta$ -Cell Dysfunction Have an Accentuated Incretin Release. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2613-2619.	1.8	16
347	Acute administration of interleukin-6 does not increase secretion of glucagon-like peptide-1 in mice. <i>Physiological Reports</i> , 2018, 6, e13788.	0.7	8
348	Non-insulin pharmacological therapies for treating type 1 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 947-960.	0.9	25
349	Pre-Meal Effect of Whey Proteins on Metabolic Parameters in Subjects with and without Type 2 Diabetes: A Randomized, Crossover Trial. <i>Nutrients</i> , 2018, 10, 122.	1.7	21
350	Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses. <i>BMC Genetics</i> , 2018, 19, 15.	2.7	12
351	Hemodynamic Effects of Glucagon: A Literature Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1804-1812.	1.8	43
352	Restoration of enteroendocrine and pancreatic function after internal hernia and short bowel syndrome in a young woman with gastric bypass - a 2-year follow-up. <i>Physiological Reports</i> , 2018, 6, e13686.	0.7	1
353	Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. <i>JCI Insight</i> , 2018, 3, .	2.3	86
354	Postprandial Effects of Individual and Combined GIP and GLP-1 Receptor Antagonization in Healthy Subjects. <i>Diabetes</i> , 2018, 67, 145-OR.	0.3	3
355	Individual and Combined Glucose-Lowering Effects of Glucagon Receptor Antagonism and Sodium-Glucose Cotransporter 2 Inhibition. <i>Diabetes</i> , 2018, 67, 1942-P.	0.3	2
356	After Roux-en-Y Gastric Bypass, Enterohepatic Bile Circulation Is Altered and Bile Acid Retention Increased while Bile Acid Homeostasis Remains Normal after Sleeve Gastrectomy. <i>Diabetes</i> , 2018, 67, .	0.3	2
357	Difference in postprandial GLP-1 response despite similar glucose kinetics after consumption of wheat breads with different particle size in healthy men. <i>European Journal of Nutrition</i> , 2017, 56, 1063-1076.	1.8	25
358	Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver $\alpha$ -Cell Axis. <i>Diabetes</i> , 2017, 66, 235-240.	0.3	144
359	Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects. <i>Bone</i> , 2017, 97, 261-266.	1.4	41
360	Hypoglycemia-Associated EEG Changes Following Antecedent Hypoglycemia in Type 1 Diabetes Mellitus. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 85-90.	2.4	14

#	ARTICLE	IF	CITATIONS
361	Patients With Long-QT Syndrome Caused by Impaired <i>hERG</i> -Encoded K <sup>v</sup> 11.1 Potassium Channel Have Exaggerated Endocrine Pancreatic and Incretin Function Associated With Reactive Hypoglycemia. <i>Circulation</i> , 2017, 135, 1705-1719.	1.6	33
362	A safety and pharmacokinetic dosing study of glucagon-like peptide 2 in infants with intestinal failure. <i>Journal of Pediatric Surgery</i> , 2017, 52, 749-754.	0.8	8
363	Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2017, 11, 1101-1111.	1.3	14
364	Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome. <i>Endocrine Connections</i> , 2017, 6, 267-277.	0.8	20
365	Role of Glucagon in Catabolism and Muscle Wasting of Critical Illness and Modulation by Nutrition. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1131-1143.	2.5	50
366	Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2017, 312, E224-E233.	1.8	41
367	Variable reliability of surrogate measures of insulin sensitivity after Roux-en-Y gastric bypass. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2017, 312, R797-R805.	0.9	15
368	A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2017, 313, E284-E291.	1.8	13
369	The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice. <i>Diabetologia</i> , 2017, 60, 1731-1739.	2.9	66
370	Colonic infusions of short-chain fatty acid mixtures promote energy metabolism in overweight/obese men: a randomized crossover trial. <i>Scientific Reports</i> , 2017, 7, 2360.	1.6	216
371	Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder. <i>JAMA Psychiatry</i> , 2017, 74, 719.	6.0	135
372	The Gut: A Key to the Pathogenesis of Type 2 Diabetes?. <i>Metabolic Syndrome and Related Disorders</i> , 2017, 15, 259-262.	0.5	10
373	Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect. <i>Diabetologia</i> , 2017, 60, 1344-1353.	2.9	14
374	Glycaemic control and weight loss with semaglutide in type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 315-317.	5.5	4
375	Interdependency of EGF and GLP-2 Signaling in Attenuating Mucosal Atrophy in a Mouse Model of Parenteral Nutrition. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2017, 3, 447-468.	2.3	29
376	The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2364-2372.	1.8	72
377	Chenodeoxycholic acid stimulates glucagon-like peptide-1 secretion in patients after Roux-en-Y gastric bypass. <i>Physiological Reports</i> , 2017, 5, e13140.	0.7	32
378	Mathematical Modelling of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 following Ingestion of Glucose. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 290-297.	1.2	8

#	ARTICLE	IF	CITATIONS
379	Glucose ingestion causes cardiac repolarization disturbances in type 1 long QT syndrome patients and healthy subjects. <i>Heart Rhythm</i> , 2017, 14, 1165-1170.	0.3	8
380	Supplementation of Diet With Galacto-oligosaccharides Increases Bifidobacteria, but Not Insulin Sensitivity, in Obese Prediabetic Individuals. <i>Gastroenterology</i> , 2017, 153, 87-97.e3.	0.6	150
381	Short-term effects of a low carbohydrate diet on glycaemic variables and cardiovascular risk markers in patients with type 1 diabetes: <sc>A</sc> randomized open-label crossover trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1479-1484.	2.2	67
382	Preserved glucagon-like peptide-1 responses to oral glucose, but reduced incretin effect, insulin secretion and sensitivity in young Asians with type 2 diabetes mellitus. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000352.	1.2	20
383	Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia. <i>Diabetologia</i> , 2017, 60, 531-540.	2.9	94
384	Pancreatic Polypeptide in Parkinson's Disease: A Potential Marker of Parasympathetic Denervation. <i>Journal of Parkinson's Disease</i> , 2017, 7, 645-652.	1.5	6
385	Acute effects of glucagon-like peptide-1, GLP-1<sub>9-36 amide</sub>, and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers. <i>Physiological Reports</i> , 2017, 5, e13102.	0.7	12
386	Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. <i>Cell Metabolism</i> , 2017, 26, 611-619.e6.	7.2	689
387	Elevated Postoperative Endogenous GLP-1 Levels Mediate Effects of Roux-en-Y Gastric Bypass on Neural Responsivity to Food Cues. <i>Diabetes Care</i> , 2017, 40, 1522-1529.	4.3	50
388	Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4153-4162.	1.8	27
389	Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass. <i>European Journal of Endocrinology</i> , 2017, 177, 455-464.	1.9	50
390	Defects in $\beta$ -Cell Function in Patients With Diabetes Due to Chronic Pancreatitis Compared With Patients With Type 2 Diabetes and Healthy Individuals. <i>Diabetes Care</i> , 2017, 40, 1314-1322.	4.3	21
391	Addition of Rye Bran and Pea Fiber to Pork Meatballs Enhances Subjective Satiety in Healthy Men, but Does Not Change Glycemic or Hormonal Responses: A Randomized Crossover Meal Test Study. <i>Journal of Nutrition</i> , 2017, 147, jn250332.	1.3	7
392	On the relationship between glucose absorption and glucose-stimulated secretion of <sc>GLP</sc>, $\alpha$ -MSH, neurotensin, and <sc>PYY</sc> from different intestinal segments in the rat. <i>Physiological Reports</i> , 2017, 5, e13507.	0.7	29
393	Instrumentalization of Eating Improves Weight Loss Maintenance in Obesity. <i>Obesity Facts</i> , 2017, 10, 633-647.	1.6	23
394	Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production. <i>Cell Reports</i> , 2017, 21, 1452-1460.	2.9	28
395	Health care professionals from developing countries report educational benefits after an online diabetes course. <i>BMC Medical Education</i> , 2017, 17, 97.	1.0	23
396	The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor. <i>Diabetes</i> , 2017, 66, 2363-2371.	0.3	88

#	ARTICLE	IF	CITATIONS
397	Why is it so difficult to measure glucagon-like peptide-1 in a mouse?. <i>Diabetologia</i> , 2017, 60, 2066-2075.	2.9	39
398	Low-Carbohydrate Diet Impairs the Effect of Glucagon in the Treatment of Insulin-Induced Mild Hypoglycemia: A Randomized Crossover Study. <i>Diabetes Care</i> , 2017, 40, 132-135.	4.3	60
399	Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes. <i>Trends in Endocrinology and Metabolism</i> , 2017, 28, 88-103.	3.1	88
400	Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference. <i>Diabetes Care</i> , 2017, 40, 109-116.	4.3	54
401	Effect of <sc>GLP</sc>â€1 receptor agonist treatment on body weight in obese antipsychoticâ€treated patients with schizophrenia: <sc>a</sc> randomized, placeboâ€controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 162-171.	2.2	53
402	The impact of <sc>EndoBarrier</sc> gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 189-199.	2.2	24
403	Addition of a dipeptidyl peptidaseâ€4 inhibitor, sitagliptin, to ongoing therapy with the glucagonâ€like peptideâ€1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 200-207.	2.2	28
404	Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: <sc>A</sc> randomized, placeboâ€controlled, doubleâ€blind, parallelâ€group study. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 773-782.	2.2	28
405	Insulin and Glucagon: Partners for Life. <i>Endocrinology</i> , 2017, 158, 696-701.	1.4	71
406	Glucagonâ€like peptideâ€1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLPâ€1 receptors. <i>Physiological Reports</i> , 2017, 5, e13503.	0.7	28
407	Semaglutide seems to be more effective the other GLP-1Ras. <i>Annals of Translational Medicine</i> , 2017, 5, 505-505.	0.7	31
408	Sweet Taste Receptor Activation in the Gut Is of Limited Importance for Glucose-Stimulated GLP-1 and GIP Secretion. <i>Nutrients</i> , 2017, 9, 418.	1.7	29
409	DPP4 gene variation affects GLP-1 secretion, insulin secretion, and glucose tolerance in humans with high body adiposity. <i>PLoS ONE</i> , 2017, 12, e0181880.	1.1	12
410	Glucagonâ€like peptideâ€1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men. <i>Physiological Reports</i> , 2017, 5, e13073.	0.7	31
411	Genetic determinants of circulating GIP and GLP-1 concentrations. <i>JCI Insight</i> , 2017, 2, .	2.3	46
412	Discovery, characterization, and clinical development of the glucagon-like peptides. <i>Journal of Clinical Investigation</i> , 2017, 127, 4217-4227.	3.9	253
413	Effects of exogenous glucagon-like peptide-2 and distal bowel resection on intestinal and systemic adaptive responses in rats. <i>PLoS ONE</i> , 2017, 12, e0181453.	1.1	13
414	Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial. <i>Diabetes Care</i> , 2016, 39, 206-213.	4.3	62



#	ARTICLE	IF	CITATIONS
415	Serum lipase activity and concentration during intravenous infusions of GLP-1 and PYY3-36 and after ad libitum meal ingestion in overweight men. <i>Physiological Reports</i> , 2016, 4, e12980.	0.7	2
416	Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-5.	1.0	33
417	Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men. <i>PLoS ONE</i> , 2016, 11, e0145890.	1.1	19
418	Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 1100-1109.	2.2	17
419	Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial. <i>Cell Metabolism</i> , 2016, 24, 63-74.	7.2	278
420	Surgical or medical therapy for patients with obesity and T2DM?. <i>Nature Reviews Endocrinology</i> , 2016, 12, 500-502.	4.3	1
421	Transcriptomic profiling of pancreatic alpha, beta and delta cell populations identifies delta cells as a principal target for ghrelin in mouse islets. <i>Diabetologia</i> , 2016, 59, 2156-2165.	2.9	169
422	Use of anesthesia dramatically alters the oral glucose tolerance and insulin secretion in C57Bl/6 mice. <i>Physiological Reports</i> , 2016, 4, e12824.	0.7	47
423	Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 310, E744-E753.	1.8	31
424	Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota. <i>Genome Medicine</i> , 2016, 8, 67.	3.6	260
425	The insulinotropic effect of exogenous glucagon-like peptide-1 is not affected by acute vagotomy in anaesthetized pigs. <i>Experimental Physiology</i> , 2016, 101, 895-912.	0.9	4
426	Comparison Of The Long-Term Effects Of Liraglutide And Glimepiride Monotherapy On Bone Mineral Density In Patients With Type 2 Diabetes. <i>Endocrine Practice</i> , 2016, 22, 406-411.	1.1	48
427	Proteomics reveals the effects of sustained weight loss on the human plasma proteome. <i>Molecular Systems Biology</i> , 2016, 12, 901.	3.2	188
428	Glucagon-like Peptide 1 Receptor Signaling in Acinar Cells Causes Growth-Dependent Release of Pancreatic Enzymes. <i>Cell Reports</i> , 2016, 17, 2845-2856.	2.9	22
429	Roles of the Gut in Glucose Homeostasis. <i>Diabetes Care</i> , 2016, 39, 884-892.	4.3	155
430	Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist. <i>Diabetes</i> , 2016, 65, 2440-2447.	0.3	43
431	Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. <i>Surgery for Obesity and Related Diseases</i> , 2016, 12, 1236-1242.	1.0	59
432	Effects of Gastric Bypass and Gastric Banding on Bone Remodeling in Obese Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 714-722.	1.8	63

#	ARTICLE	IF	CITATIONS
433	Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma. <i>EBioMedicine</i> , 2016, 7, 112-120.	2.7	53
434	Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 310, E505-E514.	1.8	56
435	No Islet Cell Hyperfunction, but Altered Gut-Islet Regulation and Postprandial Hypoglycemia in Glucose-Tolerant Patients 3 Years After Gastric Bypass Surgery. <i>Obesity Surgery</i> , 2016, 26, 2263-2267.	1.1	20
436	IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 389-397.	1.3	21
437	Integrative Genomics Outlines a Biphasic Glucose Response and a ChREBP-ROR $\alpha$ Axis Regulating Proliferation in $\beta$ Cells. <i>Cell Reports</i> , 2016, 16, 2359-2372.	2.9	34
438	The biology of glucagon and the consequences of hyperglucagonemia. <i>Biomarkers in Medicine</i> , 2016, 10, 1141-1151.	0.6	102
439	The regulation of function, growth and survival of GLP-1-producing L-cells. <i>Clinical Science</i> , 2016, 130, 79-91.	1.8	31
440	Regulation of Pancreatic $\beta$ -Cell Function and Proliferation by Bone Morphogenetic Protein 4 (BMP4) In Vitro. <i>Endocrinology</i> , 2016, 157, 3809-3820.	1.4	5
441	Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation. <i>Diabetes</i> , 2016, 65, 3473-3481.	0.3	137
442	Searching for the physiological role of glucose-dependent insulinotropic polypeptide. <i>Journal of Diabetes Investigation</i> , 2016, 7, 8-12.	1.1	30
443	Effects of Peripheral Neurotensin on Appetite Regulation and Its Role in Gastric Bypass Surgery. <i>Endocrinology</i> , 2016, 157, 3482-3492.	1.4	58
444	Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4377-4384.	1.8	12
445	Distal, not proximal, colonic acetate infusions promote fat oxidation and improve metabolic markers in overweight/obese men. <i>Clinical Science</i> , 2016, 130, 2073-2082.	1.8	165
446	Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia. <i>Endocrine Connections</i> , 2016, 5, 53-60.	0.8	2
447	Weight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levels. <i>Metabolomics</i> , 2016, 12, 1.	1.4	0
448	Dynamics of glucagon secretion in mice and rats revealed using a validated sandwich ELISA for small sample volumes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 311, E302-E309.	1.8	34
449	Gut hormones and gastric bypass. <i>Cardiovascular Endocrinology</i> , 2016, 5, 69-74.	0.8	3
450	In vivo and in vitro degradation of peptide YY <sub>3-36</sub> to inactive peptide YY <sub>3-34</sub> in humans. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2016, 310, R866-R874.	0.9	46

#	ARTICLE	IF	CITATIONS
451	Insulin Plays a Permissive Role for the Vasoactive Effect of GIP Regulating Adipose Tissue Metabolism in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3155-3162.	1.8	33
452	Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2076-2083.	1.8	24
453	Rapid gut growth but persistent delay in digestive function in the postnatal period of preterm pigs. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G550-G560.	1.6	32
454	The intestinal distribution pattern of appetite- and glucose regulatory peptides in mice, rats and pigs. <i>BMC Research Notes</i> , 2016, 9, 60.	0.6	59
455	Evidence of Extrapancreatic Glucagon Secretion in Man. <i>Diabetes</i> , 2016, 65, 585-597.	0.3	136
456	Acute disruption of glucagon secretion or action does not improve glucose tolerance in an insulin-deficient mouse model of diabetes. <i>Diabetologia</i> , 2016, 59, 363-370.	2.9	37
457	Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 221-232.	5.5	127
458	Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36. <i>European Journal of Endocrinology</i> , 2016, 174, 775-784.	1.9	72
459	Peptide production and secretion in GLUTag, NCI-H716, and STC-1 cells: a comparison to native L-cells. <i>Journal of Molecular Endocrinology</i> , 2016, 56, 201-211.	1.1	76
460	Jejunal feeding is followed by a greater rise in plasma cholecystokinin, peptide YY, glucagon-like peptide 1, and glucagon-like peptide 2 concentrations compared with gastric feeding in vivo in humans: a randomized trial. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 435-443.	2.2	17
461	Atrial Natriuretic Peptide in the High Normal Range Is Associated With Lower Prevalence of Insulin Resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1372-1380.	1.8	17
462	Glucose-Dependent Insulinotropic Polypeptide Is Associated With Lower Low-Density Lipoprotein But Unhealthy Fat Distribution, Independent of Insulin: The ADDITION-PRO Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 485-493.	1.8	46
463	GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes. <i>Diabetes Care</i> , 2016, 39, 617-624.	4.3	46
464	Major rapid weight loss induces changes in cardiac repolarization. <i>Journal of Electrocardiology</i> , 2016, 49, 467-472.	0.4	12
465	Liraglutide for treating type 1 diabetes. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 579-590.	1.4	15
466	Cephalic phase secretion of insulin and other enteropancreatic hormones in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G43-G51.	1.6	45
467	Peptide YY3-36 and glucagon-like peptide-1 in functional dyspepsia. Secretion and role in symptom generation. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 400-409.	0.6	10
468	Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 64, 908-915.	1.8	20

#	ARTICLE	IF	CITATIONS
469	GLP1- and GIP-producing cells rarely overlap and differ by bombesin receptor-2 expression and responsiveness. <i>Journal of Endocrinology</i> , 2016, 228, 39-48.	1.2	35
470	Neurotensin Is Coexpressed, Coreleased, and Acts Together With GLP-1 and PYY in Enteroendocrine Control of Metabolism. <i>Endocrinology</i> , 2016, 157, 176-194.	1.4	119
471	Regulation of gut hormone secretion. Studies using isolated perfused intestines. <i>Peptides</i> , 2016, 77, 47-53.	1.2	37
472	A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats. <i>PLoS ONE</i> , 2016, 11, e0154727.	1.1	7
473	Pancreatic $\beta$ -cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, .	0.2	36
474	Do glucagonomas always produce glucagon?. <i>Bosnian Journal of Basic Medical Sciences</i> , 2016, 16, 1-7.	0.6	14
475	Incretin hormones as a target for therapy. , 2016, , 11-30.		0
476	Vascular, but not luminal, activation of FFAR1 (GPR40) stimulates GLP-1 secretion from isolated perfused rat small intestine. <i>Physiological Reports</i> , 2015, 3, e12551.	0.7	78
477	Type 2 diabetes mellitus. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15019.	18.1	1,308
478	Preoperative $\beta$ -cell function in patients with type 2 diabetes is important for the outcome of Roux- $\epsilon$ -Y gastric bypass surgery. <i>Journal of Physiology</i> , 2015, 593, 3123-3133.	1.3	27
479	Effects of angiotensin II receptor blockade on cerebral, cardiovascular, counter-regulatory, and symptomatic responses during hypoglycaemia in patients with type 1 diabetes. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015, 16, 1036-1045.	1.0	6
480	Resistant starch and protein intake enhances fat oxidation and feelings of fullness in lean and overweight/obese women. <i>Nutrition Journal</i> , 2015, 14, 113.	1.5	50
481	Gastric bypass surgery has a weight-loss independent effect on post-challenge serum glucose levels. <i>Diabetology and Metabolic Syndrome</i> , 2015, 7, 69.	1.2	2
482	Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1522-1528.	1.4	15
483	Gastric emptying and disease activity in inflammatory bowel disease. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1234-1242.	1.7	38
484	L-Glutamine and Whole Protein Restore First-Phase Insulin Response and Increase Glucagon-Like Peptide-1 in Type 2 Diabetes Patients. <i>Nutrients</i> , 2015, 7, 2101-2108.	1.7	17
485	The Use of Gastrostomy Tube for the Long-Term Remission of Hyperinsulinemic Hypoglycemia After Roux-en-y Gastric Bypass: A Case Report. <i>AACE Clinical Case Reports</i> , 2015, 1, e84-e87.	0.4	14
486	Effect of Antibiotics on Gut Microbiota, Gut Hormones and Glucose Metabolism. <i>PLoS ONE</i> , 2015, 10, e0142352.	1.1	85

#	ARTICLE	IF	CITATIONS
487	Infrared thermographic assessment of changes in skin temperature during hypoglycaemia in patients with type 1 diabetes. <i>Diabetologia</i> , 2015, 58, 1898-1906.	2.9	9
488	Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study. <i>BMJ Open</i> , 2015, 5, e007791-e007791.	0.8	12
489	Bile acid mediated effects on gut integrity and performance of early-weaned piglets. <i>BMC Veterinary Research</i> , 2015, 11, 111.	0.7	24
490	An Analysis of Cosecretion and Coexpression of Gut Hormones From Male Rat Proximal and Distal Small Intestine. <i>Endocrinology</i> , 2015, 156, 847-857.	1.4	128
491	Incretin Effect After Oral Amino Acid Ingestion in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1172-1176.	1.8	58
492	Stability of glucagon-like peptide 1 and glucagon in human plasma. <i>Endocrine Connections</i> , 2015, 4, 50-57.	0.8	65
493	The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2015, 309, R544-R551.	0.9	22
494	Early gradual feeding with bovine colostrum improves gut function and NEC resistance relative to infant formula in preterm pigs. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, G310-G323.	1.6	80
495	Patients with psoriasis are insulin resistant. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 599-605.	0.6	62
496	Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 413-421.	1.2	53
497	Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 308, E535-E544.	1.8	62
498	Dairy proteins, dairy lipids, and postprandial lipemia in persons with abdominal obesity (DairyHealth): a 12-wk, randomized, parallel-controlled, double-blinded, diet intervention study. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 870-878.	2.2	43
499	Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 445-450.	1.2	61
500	GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. <i>Diabetes</i> , 2015, 64, 2513-2525.	0.3	235
501	The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes. <i>Diabetologia</i> , 2015, 58, 828-834.	2.9	21
502	Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance. <i>Diabetologia</i> , 2015, 58, 920-928.	2.9	27
503	Intake of <i>Lactobacillus reuteri</i> Improves Incretin and Insulin Secretion in Glucose-Tolerant Humans: A Proof of Concept. <i>Diabetes Care</i> , 2015, 38, 1827-1834.	4.3	194
504	Pancreatic polypeptide responses to isoglycemic oral and intravenous glucose in humans with and without intact vagal innervation. <i>Peptides</i> , 2015, 71, 229-231.	1.2	15

#	ARTICLE	IF	CITATIONS
505	GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2909-2917.	1.8	116
506	Liraglutide for Type 2 diabetes and obesity: a 2015 update. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 753-767.	0.6	62
507	Important species differences regarding lymph contribution to gut hormone responses. <i>Peptides</i> , 2015, 71, 28-31.	1.2	5
508	The 2-monoacylglycerol moiety of dietary fat appears to be responsible for the fat-induced release of GLP-1 in humans. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 548-555.	2.2	59
509	Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes. <i>Diabetologia</i> , 2015, 58, 2254-2258.	2.9	94
510	Glucose stimulates neurotensin secretion from the rat small intestine by mechanisms involving SGLT1 and GLUT2, leading to cell depolarization and calcium influx. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 308, E1123-E1130.	1.8	34
511	Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 308, E641-E649.	1.8	63
512	Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 308, F867-F877.	1.3	89
513	WEIGHT LOSS BUT NOT EXERCISE LOWERS GLUCAGON RESPONSE AND IMPROVES GLUCAGON-LIKE PEPTIDE-1 TO INSULIN RATIO IN PREDIABETIC PATIENTS WITH CORONARY ARTERY DISEASE: THE RANDOMIZED CUT-IT TRIAL. <i>Journal of the American College of Cardiology</i> , 2015, 65, A1511.	1.2	0
514	The glucagon-like peptide 2 receptor is expressed in enteric neurons and not in the epithelium of the intestine. <i>Peptides</i> , 2015, 67, 20-28.	1.2	40
515	Differential effects of glucagon-like peptide-1 on microvascular recruitment and glucose metabolism in short- and long-term insulin resistance. <i>Journal of Physiology</i> , 2015, 593, 2185-2198.	1.3	20
516	Incretin and Glucagon Levels in Adult Offspring Exposed to Maternal Diabetes in Pregnancy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1967-1975.	1.8	16
517	Improvements in Glucose Metabolism Early After Gastric Bypass Surgery Are Not Explained by Increases in Total Bile Acids and Fibroblast Growth Factor 19 Concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E396-E406.	1.8	89
518	Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young. <i>European Journal of Endocrinology</i> , 2015, 173, 205-215.	1.9	11
519	Updates in weight loss surgery and gastrointestinal peptides. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 21-28.	1.2	24
520	Hypoglycemia-Associated Changes in the Electroencephalogram in Patients With Type 1 Diabetes and Normal Hypoglycemia Awareness or Unawareness. <i>Diabetes</i> , 2015, 64, 1760-1769.	0.3	33
521	Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. <i>Diabetologia</i> , 2015, 58, 2688-2698.	2.9	72
522	The structure of wheat bread influences the postprandial metabolic response in healthy men. <i>Food and Function</i> , 2015, 6, 3236-3248.	2.1	30

#	ARTICLE	IF	CITATIONS
523	Bile Acids Trigger GLP-1 Release Predominantly by Accessing Basolaterally Located G Protein-Coupled Bile Acid Receptors. <i>Endocrinology</i> , 2015, 156, 3961-3970.	1.4	253
524	Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study. <i>Diabetes Care</i> , 2015, 38, 2250-2257.	4.3	91
525	Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 600-607.	2.2	50
526	Sensing of triacylglycerol in the gut: different mechanisms for fatty acids and 2- $\mu$ monoacylglycerol. <i>Journal of Physiology</i> , 2015, 593, 2097-2109.	1.3	17
527	Specific inhibition of bile acid transport alters plasma lipids and GLP-1. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 75.	0.7	49
528	Effect of Oxymodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4541-4552.	1.8	65
529	The Effects of TNF- $\alpha$ on GLP-1-Stimulated Plasma Glucose Kinetics. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E616-E622.	1.8	18
530	Response to Comment on FÃ¼rch et al. GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. <i>Diabetes</i> 2015;64:2513-2525. <i>Diabetes</i> , 2015, 64, e30-e31.	0.3	1
531	Transcriptional and Functional Characterization of the G Protein-Coupled Receptor Repertoire of Gastric Somatostatin Cells. <i>Endocrinology</i> , 2015, 156, 3909-3923.	1.4	56
532	Clearance of glucoregulatory peptide hormones during haemodialysis and haemodiafiltration in non-diabetic end-stage renal disease patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 513-520.	0.4	16
533	The anorexic hormone Peptide YY <sub>3-36</sub> is rapidly metabolized to inactive Peptide YY <sub>3-34</sub> in vivo. <i>Physiological Reports</i> , 2015, 3, e12455.	0.7	23
534	Inability to match energy intake with energy expenditure at sustained near-maximal rates of energy expenditure in older men during a 14-d cycling expedition. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 1398-1405.	2.2	21
535	Glucose-Dependent Insulinotropic Polypeptide Augments Glucagon Responses to Hypoglycemia in Type 1 Diabetes. <i>Diabetes</i> , 2015, 64, 72-78.	0.3	60
536	Molecular Mechanisms of Glucose-Stimulated GLP-1 Secretion From Perfused Rat Small Intestine. <i>Diabetes</i> , 2015, 64, 370-382.	0.3	132
537	Autonomic Diabetic Neuropathy Impairs Glucose and Dipeptidyl Peptidase 4 Inhibitor-Regulated Glucagon Concentration in Type 1 Diabetic Patients. <i>Journal of Endocrinology and Metabolism</i> , 2015, 5, 229-237.	0.1	3
538	GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2015, 2015, 150049.	0.2	10
539	Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2015, 2015, 150105.	0.2	7
540	Influence of GLP-1 on Myocardial Glucose Metabolism in Healthy Men during Normo- or Hypoglycemia. <i>PLoS ONE</i> , 2014, 9, e83758.	1.1	21

#	ARTICLE	IF	CITATIONS
541	A 25-Year-Old Woman with Type 2 Diabetes and Liver Disease. <i>Case Reports in Gastroenterology</i> , 2014, 8, 398-403.	0.3	2
542	Glutamate prevents intestinal atrophy via luminal nutrient sensing in a mouse model of total parenteral nutrition. <i>FASEB Journal</i> , 2014, 28, 2073-2087.	0.2	40
543	Effects of hydrolysed casein, intact casein and intact whey protein on energy expenditure and appetite regulation: a randomised, controlled, cross-over study. <i>British Journal of Nutrition</i> , 2014, 112, 1412-1422.	1.2	28
544	Glucose-Dependent Insulinotropic Polypeptide Inhibits Bone Resorption in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2325-E2329.	1.8	104
545	The Authors Reply. <i>Kidney International</i> , 2014, 85, 212-213.	2.6	0
546	The use of double-balloon enteroscopy in retrieving mucosal biopsies from the entire human gastrointestinal tract. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1143-1149.	0.6	6
547	Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. <i>Endocrine Connections</i> , 2014, 3, 11-16.	0.8	50
548	On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes. <i>Endocrine Connections</i> , 2014, 3, 193-199.	0.8	2
549	Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial. <i>BMJ Open</i> , 2014, 4, e004227.	0.8	15
550	KCNQ1 Long QT Syndrome Patients Have Hyperinsulinemia and Symptomatic Hypoglycemia. <i>Diabetes</i> , 2014, 63, 1315-1325.	0.3	61
551	The Melanocortin-4 Receptor Is Expressed in Enteroendocrine L Cells and Regulates the Release of Peptide YY and Glucagon-like Peptide 1 In Vivo. <i>Cell Metabolism</i> , 2014, 20, 1018-1029.	7.2	139
552	Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 451-456.	2.2	12
553	Insulin Resistance Alters Islet Morphology in Nondiabetic Humans. <i>Diabetes</i> , 2014, 63, 994-1007.	0.3	152
554	Targeting the intestinal L-cell for obesity and type 2 diabetes treatment. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 61-72.	1.2	24
555	Defining the Role of GLP-1 in the Enteroinsular Axis in Type 2 Diabetes Using DPP-4 Inhibition and GLP-1 Receptor Blockade. <i>Diabetes</i> , 2014, 63, 1079-1092.	0.3	84
556	Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. <i>European Journal of Endocrinology</i> , 2014, 170, 529-538.	1.9	116
557	GLP-1 as a Mediator in the Remission of Type 2 Diabetes After Gastric Bypass and Sleeve Gastrectomy Surgery. <i>Diabetes</i> , 2014, 63, 3172-3174.	0.3	49
558	GLP-1 Responses Are Heritable and Blunted in Acquired Obesity With High Liver Fat and Insulin Resistance. <i>Diabetes Care</i> , 2014, 37, 242-251.	4.3	53



#	ARTICLE	IF	CITATIONS
559	GLP-1 amidation efficiency along the length of the intestine in mice, rats and pigs and in GLP-1 secreting cell lines. <i>Peptides</i> , 2014, 55, 52-57.	1.2	52
560	Distal Gastrectomy in Pancreaticoduodenectomy is Associated with Accelerated Gastric Emptying, Enhanced Postprandial Release of GLP-1, and Improved Insulin Sensitivity. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 52-59.	0.9	12
561	Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and $\alpha$ -celso glycemica€•Intravenous Glucose. <i>Diabetes</i> , 2014, 63, 663-674.	0.3	80
562	Incretin Effect and Glucagon Responses to Oral and Intravenous Glucose in Patients With Maturity-Onset Diabetes of the Young–Type 2 and Type 3. <i>Diabetes</i> , 2014, 63, 2838-2844.	0.3	43
563	Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E418-E426.	1.8	79
564	Normal physical activity obliterates the deleterious effects of a high-caloric intake. <i>Journal of Applied Physiology</i> , 2014, 116, 231-239.	1.2	44
565	Consumption of a Diet Low in Advanced Glycation End Products for 4 Weeks Improves Insulin Sensitivity in Overweight Women. <i>Diabetes Care</i> , 2014, 37, 88-95.	4.3	102
566	Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1. <i>European Journal of Endocrinology</i> , 2014, 171, 407-419.	1.9	56
567	Early Enhancements of Hepatic and Later of Peripheral Insulin Sensitivity Combined With Increased Postprandial Insulin Secretion Contribute to Improved Glycemic Control After Roux-en-Y Gastric Bypass. <i>Diabetes</i> , 2014, 63, 1725-1737.	0.3	220
568	GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2014, 306, E355-E362.	1.8	51
569	Effects of PYY <sub>3-36</sub> and GLP-1 on energy intake, energy expenditure, and appetite in overweight men. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2014, 306, E1248-E1256.	1.8	114
570	Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 306, G622-G630.	1.6	94
571	<i>Lactobacillus paracasei</i> subsp <i>paracasei</i> L. casei W8 suppresses energy intake acutely. <i>Appetite</i> , 2014, 82, 111-118.	1.8	26
572	Therapies for inter-relating diabetes and obesity – GLP-1 and obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2487-2500.	0.9	37
573	High saturated fatty acid intake induces insulin secretion by elevating gastric inhibitory polypeptide levels in healthy individuals. <i>Nutrition Research</i> , 2014, 34, 653-660.	1.3	22
574	Mechanisms behind the superior effects of interval vs continuous training on glycaemic control in individuals with type 2 diabetes: a randomised controlled trial. <i>Diabetologia</i> , 2014, 57, 2081-2093.	2.9	70
575	Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals. <i>Diabetologia</i> , 2014, 57, 1720-1725.	2.9	56
576	Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?. <i>Diabetologia</i> , 2014, 57, 1919-1926.	2.9	156

#	ARTICLE	IF	CITATIONS
577	Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report. <i>BMC Research Notes</i> , 2014, 7, 326.	0.6	1
578	Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 119-127.	0.4	14
579	Elimination and Degradation of Glucagon-like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Patients with End-Stage Renal Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2457-2466.	1.8	31
580	Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (<sc>GLP</sc>1): implications for <sc>GLP</sc>1 measurements in clinical studies. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 1155-1164.	2.2	85
581	Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist: A Double-Blind, Randomized, Crossover Trial. <i>Diabetes Care</i> , 2014, 37, 1797-1805.	4.3	94
582	Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs. <i>Regulatory Peptides</i> , 2014, 188, 70-80.	1.9	29
583	Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 152-164.	5.5	248
584	Glycemic Effects and Safety of L-Glutamine Supplementation with or without Sitagliptin in Type 2 Diabetes Patients—A Randomized Study. <i>PLoS ONE</i> , 2014, 9, e113366.	1.1	21
585	Glucometabolic Hormones and Cardiovascular Risk Markers in Antipsychotic-Treated Patients. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e899-e905.	1.1	19
586	Combining <sc>GLP</sc>1 receptor agonists with insulin: therapeutic rationales and clinical findings. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 3-14.	2.2	56
587	Effects of a meal rich in medium-chain saturated fat on postprandial lipemia in relatives of type 2 diabetics. <i>Nutrition</i> , 2013, 29, 1000-1006.	1.1	4
588	Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2047-2058.	0.9	102
589	Effects of gastric bypass surgery on glucose absorption and metabolism during a mixed meal in glucose-tolerant individuals. <i>Diabetologia</i> , 2013, 56, 2250-2254.	2.9	100
590	Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?. <i>Diabetologia</i> , 2013, 56, 1869-1872.	2.9	6
591	Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. <i>Journal of Gastroenterology</i> , 2013, 48, 322-332.	2.3	41
592	Is there a place for incretin therapies in obesity and prediabetes?. <i>Trends in Endocrinology and Metabolism</i> , 2013, 24, 145-152.	3.1	38
593	The L-arginine amino acid receptor GPRC6A is expressed in the islets of Langerhans but is not involved in L-arginine-induced insulin release. <i>Amino Acids</i> , 2013, 44, 383-390.	1.2	46
594	Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. <i>Current Opinion in Pharmacology</i> , 2013, 13, 983-988.	1.7	96

#	ARTICLE	IF	CITATIONS
595	Islet-cell dysfunction induced by glucocorticoid treatment: potential role for altered sympathovagal balance?. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 568-577.	1.5	26
596	Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass. <i>Diabetologia</i> , 2013, 56, 2679-2687.	2.9	82
597	Copenhagen study of overweight patients with coronary artery disease undergoing low energy diet or interval training: the randomized CUT-IT trial protocol. <i>BMC Cardiovascular Disorders</i> , 2013, 13, 106.	0.7	15
598	Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3346-3352.	4.3	125
599	Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT. <i>European Journal of Endocrinology</i> , 2013, 169, 421-430.	1.9	52
600	Appetite regulation in overweight, sedentary men after different amounts of endurance exercise: a randomized controlled trial. <i>Journal of Applied Physiology</i> , 2013, 115, 1599-1609.	1.2	28
601	Tumour necrosis factor- $\alpha$ infusion produced insulin resistance but no change in the incretin effect in healthy volunteers. <i>Diabetes/Metabolism Research and Reviews</i> , 2013, 29, 655-663.	1.7	20
602	Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis. <i>Gut</i> , 2013, 62, 1724-1733.	6.1	50
603	Regulation of urea synthesis during the acute-phase response in rats. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, G680-G686.	1.6	15
604	Effects of oleic acid and olive oil on gastric emptying, gut hormone secretion and Appetite in lean and overweight or obese males. <i>E-SPEN Journal</i> , 2013, 8, e8-e14.	0.5	11
605	Relationships among tonic and episodic aspects of motivation to eat, gut peptides, and weight before and after bariatric surgery. <i>Surgery for Obesity and Related Diseases</i> , 2013, 9, 802-808.	1.0	28
606	Acute differential effects of dietary protein quality on postprandial lipemia in obese non-diabetic subjects. <i>Nutrition Research</i> , 2013, 33, 34-40.	1.3	56
607	Reduction in cardiovascular risk factors and insulin dose, but no beta-cell regeneration 1 year after Roux-en-Y gastric bypass in an obese patient with type 1 diabetes: A case report. <i>Obesity Research and Clinical Practice</i> , 2013, 7, e269-e274.	0.8	18
608	Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure. <i>Regulatory Peptides</i> , 2013, 181, 4-8.	1.9	28
609	Removal of Duodenum Elicits GLP-1 Secretion. <i>Diabetes Care</i> , 2013, 36, 1641-1646.	4.3	28
610	Increased Hepatic Insulin Clearance After Roux-en-Y Gastric Bypass. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1066-E1071.	1.8	66
611	Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease. <i>Kidney International</i> , 2013, 83, 915-923.	2.6	29
612	The <i>CTRB1/2</i> Locus Affects Diabetes Susceptibility and Treatment via the Incretin Pathway. <i>Diabetes</i> , 2013, 62, 3275-3281.	0.3	96

#	ARTICLE	IF	CITATIONS
613	Early growth and postprandial appetite regulatory hormone responses. <i>British Journal of Nutrition</i> , 2013, 110, 1591-1600.	1.2	11
614	Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study. <i>BMJ Open</i> , 2013, 3, e002764.	0.8	11
615	The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial. <i>BMJ Open</i> , 2013, 3, e003834.	0.8	9
616	Bile Acids Induce Glucagon-Like Peptide 2 Secretion with Limited Effects on Intestinal Adaptation in Early Weaned Pigs. <i>Journal of Nutrition</i> , 2013, 143, 1899-1905.	1.3	22
617	Evidence for paracrine/autocrine regulation of GLP-1-producing cells. <i>American Journal of Physiology - Cell Physiology</i> , 2013, 305, C1041-C1049.	2.1	20
618	Contribution of gastroenteropancreatic appetite hormones to protein-induced satiety. <i>American Journal of Clinical Nutrition</i> , 2013, 97, 980-989.	2.2	135
619	Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, G413-G419.	1.6	43
620	The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, G1117-G1127.	1.6	138
621	Glucagon-like peptide-2 induces rapid digestive adaptation following intestinal resection in preterm neonates. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, G277-G285.	1.6	48
622	Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty. <i>European Journal of Endocrinology</i> , 2013, 169, 187-201.	1.9	51
623	Exaggerated Glucagon-Like Peptide 1 Response Is Important for Improved $\beta$ -Cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2013, 62, 3044-3052.	0.3	262
624	Long-Term Effects of Bariatric Surgery on Meal Disposal and $\beta$ -Cell Function in Diabetic and Nondiabetic Patients. <i>Diabetes</i> , 2013, 62, 3709-3717.	0.3	98
625	Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. <i>Experimental Dermatology</i> , 2013, 22, 150-152.	1.4	25
626	GLP 1/2, Enteroglucagon, Glicentin, and Oxyntomodulin. , 2013, , 1241-1250.		2
627	Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E664-E671.	1.8	151
628	GLP-1 Delays but Does Not Prevent the Onset of Necrotizing Enterocolitis in Preterm Pigs. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2013, 56, 623-630.	0.9	18
629	Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain. <i>Frontiers in Neuroenergetics</i> , 2013, 5, 2.	5.3	25
630	A Pilot Study Examining the Relationship among Crohn Disease Activity, Glucagon-Like Peptide-2 Signalling and Intestinal Function in Pediatric Patients. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2013, 27, 587-592.	1.8	13

#	ARTICLE	IF	CITATIONS
631	Influence of Erythropoietin on Cognitive Performance during Experimental Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Randomized Cross-Over Trial. <i>PLoS ONE</i> , 2013, 8, e59672.	1.1	22
632	Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes. <i>PLoS ONE</i> , 2013, 8, e73154.	1.1	38
633	Intestinal Adaptation Is Stimulated by Partial Enteral Nutrition Supplemented With the Prebiotic Short-Chain Fructooligosaccharide in a Neonatal Intestinal Failure Piglet Model. <i>Journal of Parenteral and Enteral Nutrition</i> , 2012, 36, 524-537.	1.3	37
634	Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, G610-G622.	1.6	18
635	Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, G218-G224.	1.6	103
636	The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, G815-G823.	1.6	14
637	Impaired Incretin-Induced Amplification of Insulin Secretion after Glucose Homeostatic Dysregulation in Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1363-1370.	1.8	61
638	Treatment of adult short bowel syndrome patients with teduglutide. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 235-243.	0.9	19
639	Effects of Everyday Life Events on Glucose, Insulin, and Glucagon Dynamics in Continuous Subcutaneous Insulin Infusion-Treated Type 1 Diabetes: Collection of Clinical Data for Glucose Modeling. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 210-217.	2.4	17
640	Alcohol Intake and Its Effect on Some Appetite-Regulating Hormones in Man: Influence of Gastroprotection with Sucralfate. <i>Endocrine Research</i> , 2012, 37, 154-162.	0.6	23
641	Continuous Parenteral and Enteral Nutrition Induces Metabolic Dysfunction in Neonatal Pigs. <i>Journal of Parenteral and Enteral Nutrition</i> , 2012, 36, 538-550.	1.3	47
642	Molecular mechanisms of lipoapoptosis and metformin protection in GLP-1 secreting cells. <i>Biochemical and Biophysical Research Communications</i> , 2012, 427, 91-95.	1.0	16
643	Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. <i>Regulatory Peptides</i> , 2012, 179, 91-100.	1.9	81
644	A Major Lineage of Enteroendocrine Cells Coexpress CCK, Secretin, GIP, GLP-1, PYY, and Neurotensin but Not Somatostatin. <i>Endocrinology</i> , 2012, 153, 5782-5795.	1.4	269
645	GPR119 as a fat sensor. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 374-381.	4.0	165
646	Glucagon-Like Peptide-1 Decreases Intracerebral Glucose Content by Activating Hexokinase and Changing Glucose Clearance during Hyperglycemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 2146-2152.	2.4	40
647	The glycemic, insulinemic and plasma amino acid responses to equi-carbohydrate milk meals, a pilot-study of bovine and human milk. <i>Nutrition Journal</i> , 2012, 11, 83.	1.5	44
648	The insulinogenic effect of whey protein is partially mediated by a direct effect of amino acids and GIP on $\beta$ -cells. <i>Nutrition and Metabolism</i> , 2012, 9, 48.	1.3	88

#	ARTICLE	IF	CITATIONS
649	Impaired Crosstalk between Pulsatile Insulin and Glucagon Secretion in Prediabetic Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E791-E795.	1.8	34
650	Examining the Effects of Hyperglycemia on Pancreatic Endocrine Function in Humans: Evidence for <i>in Vivo</i> Glucotoxicity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 4682-4691.	1.8	44
651	Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2012, 33, 1491-1499.	1.0	456
652	Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2012, 32, 1-14.	1.1	29
653	The effect of a very low calorie diet on insulin sensitivity, beta cell function, insulin clearance, incretin hormone secretion, androgen levels and body composition in obese young women. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2012, 72, 410-419.	0.6	42
654	Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2012, 3, 10.	1.2	46
655	Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 39-48.	1.1	37
656	The effect of glucagon-like peptide 1 on cardiovascular risk. <i>Nature Reviews Cardiology</i> , 2012, 9, 209-222.	6.1	131
657	Incretin based therapies: Do they hold their promise?. <i>Journal of Diabetes</i> , 2012, 4, 4-7.	0.8	1
658	Effects of Pre-Meal Drinks with Protein and Amino Acids on Glycemic and Metabolic Responses at a Subsequent Composite Meal. <i>PLoS ONE</i> , 2012, 7, e44731.	1.1	61
659	The contribution of gastrointestinal appetite hormones to protein-induced satiety. <i>FASEB Journal</i> , 2012, 26, 40.5.	0.2	0
660	IL-6 has no acute effect on the regulation of urea synthesis in vivo in rats. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2011, 71, 150-156.	0.6	7
661	Neuroprotective properties of GLP-1: theoretical and practical applications. <i>Current Medical Research and Opinion</i> , 2011, 27, 547-558.	0.9	125
662	2-Oleoyl Glycerol Is a GPR119 Agonist and Signals GLP-1 Release in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1409-E1417.	1.8	238
663	Loss of Inverse Relationship Between Pulsatile Insulin and Glucagon Secretion in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2011, 60, 2160-2168.	0.3	104
664	The Effect of PCSK1 Variants on Waist, Waist-Hip Ratio and Glucose Metabolism Is Modified by Sex and Glucose Tolerance Status. <i>PLoS ONE</i> , 2011, 6, e23907.	1.1	23
665	Glucagon like peptide 1 receptor and the liver. <i>Liver International</i> , 2011, 31, 1243-1245.	1.9	10
666	Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndrome. <i>Surgery</i> , 2011, 150, 217-223.	1.0	28

#	ARTICLE	IF	CITATIONS
667	Genetic variation within the TRPM5 locus associates with prediabetic phenotypes in subjects at increased risk for type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 1325-1333.	1.5	47
668	Gastric emptying, glucose metabolism and gut hormones: Evaluation of a common preoperative carbohydrate beverage. <i>Nutrition</i> , 2011, 27, 897-903.	1.1	21
669	The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunosomy short bowel patients. <i>Regulatory Peptides</i> , 2011, 168, 32-38.	1.9	77
670	Lixisenatide for type 2 diabetes mellitus. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 549-557.	1.9	70
671	Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011, 38, 713-725.	0.8	13
672	Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs. <i>Diabetologia</i> , 2011, 54, 2206-2208.	2.9	66
673	Gastric Emptying of Orally Administered Glucose Solutions and Incretin Hormone Responses Are Unaffected by Laparoscopic Adjustable Gastric Banding. <i>Obesity Surgery</i> , 2011, 21, 625-632.	1.1	31
674	Delayed Î²-cell response and glucose intolerance in young women with Turner syndrome. <i>BMC Endocrine Disorders</i> , 2011, 11, 6.	0.9	33
675	Postprandial Insulin Secretion After Gastric Bypass Surgery. <i>Diabetes</i> , 2011, 60, 2203-2205.	0.3	34
676	GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes. <i>Diabetes</i> , 2011, 60, 1270-1276.	0.3	141
677	Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, S251-S257.	4.3	233
678	Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as Î±celso glycemicaâ€•Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 945-954.	1.8	60
679	Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice. <i>Endocrinology</i> , 2011, 152, 3018-3029.	1.4	134
680	The effects of l-arabinose on intestinal sucrase activity: dose-response studies in vitro and in humans. <i>American Journal of Clinical Nutrition</i> , 2011, 94, 472-478.	2.2	77
681	A Low Glycemic Index Diet Does Not Affect Postprandial Energy Metabolism but Decreases Postprandial Insulinemia and Increases Fullness Ratings in Healthy Women. <i>Journal of Nutrition</i> , 2011, 141, 1679-1684.	1.3	39
682	Increased Postprandial GIP and Glucagon Responses, But Unaltered GLP-1 Response after Intervention with Steroid Hormone, Relative Physical Inactivity, And High-Calorie Diet in Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 447-453.	1.8	152
683	Increased postprandial glycaemia, insulinemia, and lipidemia after 10 weeksâ€™ sucrose-rich diet compared to an artificially sweetened diet: a randomised controlled trial. <i>Food and Nutrition Research</i> , 2011, 55, 5961.	1.2	71
684	Rapid Tachyphylaxis of the Glucagon-Like Peptide 1â€™Induced Deceleration of Gastric Emptying in Humans. <i>Diabetes</i> , 2011, 60, 1561-1565.	0.3	291

#	ARTICLE	IF	CITATIONS
685	Transgenic Rescue of Adipocyte Glucose-dependent Insulinotropic Polypeptide Receptor Expression Restores High Fat Diet-induced Body Weight Gain. <i>Journal of Biological Chemistry</i> , 2011, 286, 44632-44645.	1.6	37
686	Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual $\beta$ -Cell Function. <i>Diabetes</i> , 2011, 60, 1599-1607.	0.3	131
687	Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual $\beta$ -Cell Function. <i>Diabetes Care</i> , 2011, 34, 1463-1468.	4.3	143
688	Women with bulimia nervosa exhibit attenuated secretion of glucagon-like peptide 1, pancreatic polypeptide, and insulin in response to a meal. <i>American Journal of Clinical Nutrition</i> , 2011, 94, 967-972.	2.2	37
689	Glucose-Dependent Insulinotropic Polypeptide. <i>Diabetes</i> , 2011, 60, 3103-3109.	0.3	265
690	Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 737-745.	1.8	190
691	Glutamine Reduces Postprandial Glycemia and Augments the Glucagon-Like Peptide-1 Response in Type 2 Diabetes Patients. <i>Journal of Nutrition</i> , 2011, 141, 1233-1238.	1.3	85
692	Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 428-435.	0.6	27
693	The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2011, 300, E1038-E1046.	1.8	148
694	Incretin Hormone and Insulin Responses to Oral versus Intravenous Lipid Administration in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2519-2524.	1.8	161
695	The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. <i>Clinical Endocrinology</i> , 2010, 73, 189-196.	1.2	54
696	Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2010, 17, 57-62.	1.2	49
697	The Intestinotrophic Peptide, GLP-2, Counteracts the Gastrointestinal Atrophy in Mice Induced by the Epidermal Growth Factor Receptor Inhibitor, Erlotinib, and Cisplatin. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2785-2796.	1.1	26
698	Effects of meal size and composition on incretin, $\beta$ -cell, and $\beta$ -cell responses. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 502-511.	1.5	55
699	Dipeptidyl peptidase expression during experimental colitis in mice. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1340-1351.	0.9	44
700	Postprandial Diabetic Glucose Tolerance Is Normalized by Gastric Bypass Feeding as Opposed to Gastric Feeding and Is Associated With Exaggerated GLP-1 Secretion. <i>Diabetes Care</i> , 2010, 33, 375-377.	4.3	105
701	Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets. <i>European Journal of Endocrinology</i> , 2010, 162, 75-83.	1.9	31
702	The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action. <i>Diabetes</i> , 2010, 59, 1765-1770.	0.3	230



#	ARTICLE	IF	CITATIONS
703	The T-Allele of TCF7L2 rs7903146 Associates With a Reduced Compensation of Insulin Secretion for Insulin Resistance Induced by 9 Days of Bed Rest. <i>Diabetes</i> , 2010, 59, 836-843.	0.3	34
704	Effect of growth in infancy on body composition, insulin resistance, and concentration of appetite hormones in adolescence. <i>American Journal of Clinical Nutrition</i> , 2010, 91, 1675-1683.	2.2	40
705	Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans. <i>Diabetes</i> , 2010, 59, 2160-2163.	0.3	126
706	Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 298, G419-G424.	1.6	96
707	Sex Steroids Affect Triglyceride Handling, Glucose-Dependent Insulinotropic Polypeptide, and Insulin Sensitivity. <i>Diabetes Care</i> , 2010, 33, 1831-1833.	4.3	31
708	A Cereal-Based Evening Meal Rich in Indigestible Carbohydrates Increases Plasma Butyrate the Next Morning. <i>Journal of Nutrition</i> , 2010, 140, 1932-1936.	1.3	101
709	Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2010, 298, E832-E837.	1.8	67
710	On the role of glucose-dependent insulinotropic polypeptide in postprandial metabolism in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2010, 298, E614-E621.	1.8	64
711	Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010, 298, H1096-H1102.	1.5	141
712	Effect of Glucagon-Like Peptide-1 on $\hat{I}^{\pm}$ - and $\hat{I}^2$ -Cell Function in C-Peptide-Negative Type 1 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2492-2496.	1.8	45
713	Do the Actions of Glucagon-Like Peptide-1 on Gastric Emptying, Appetite, and Food Intake Involve Release of Amylin in Humans?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2367-2375.	1.8	31
714	Secretion and Dipeptidyl Peptidase-4-Mediated Metabolism of Incretin Hormones after a Mixed Meal or Glucose Ingestion in Obese Compared to Lean, Nondiabetic Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 872-878.	1.8	127
715	Impact of Exogenous Hyperglucagonemia on Postprandial Concentrations of Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4061-4065.	1.8	6
716	Sustained glucagon-like peptide-2 infusion is required for intestinal adaptation, and cessation reverses increased cellularity in rats with intestinal failure. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, G1222-G1230.	1.6	22
717	Increased Postprandial Response of Glucagon-Like Peptide-2 in Patients with Chronic Pancreatitis and Pancreatic Exocrine Insufficiency. <i>Pancreatology</i> , 2010, 10, 201-207.	0.5	8
718	The influence of nutrients, biliary-pancreatic secretions, and systemic trophic hormones on intestinal adaptation in a Roux-en-Y bypass model. <i>Journal of Pediatric Surgery</i> , 2010, 45, 987-995.	0.8	78
719	Automated detection of hypoglycemia-induced EEG changes recorded by subcutaneous electrodes in subjects with type 1 diabetes—The brain as a biosensor. <i>Diabetes Research and Clinical Practice</i> , 2010, 88, 22-28.	1.1	51
720	Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes. <i>Biochemical and Biophysical Research Communications</i> , 2010, 393, 410-413.	1.0	32

#	ARTICLE	IF	CITATIONS
721	The effect of glucagon-like peptide-2 on arterial blood flow and cardiac parameters. <i>Regulatory Peptides</i> , 2010, 159, 67-71.	1.9	32
722	Pancreatic $\beta$ -cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes. <i>Regulatory Peptides</i> , 2010, 160, 175-180.	1.9	6
723	Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. <i>Regulatory Peptides</i> , 2010, 163, 96-101.	1.9	18
724	Little enhancement of meal-induced glucagon-like peptide-1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls. <i>Journal of Diabetes Investigation</i> , 2010, 1, 56-59.	1.1	80
725	Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 133-140.	1.9	112
726	Incretin-Based Therapy of Type 2 Diabetes Mellitus. <i>Current Protein and Peptide Science</i> , 2009, 10, 46-55.	0.7	40
727	Mechanisms of gastric emptying disturbances in chronic and acute inflammation of the distal gastrointestinal tract. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, G861-G868.	1.6	45
728	Effects of 1 and 3 g cinnamon on gastric emptying, satiety, and postprandial blood glucose, insulin, glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and ghrelin concentrations in healthy subjects. <i>American Journal of Clinical Nutrition</i> , 2009, 89, 815-821.	2.2	123
729	Natural History of Insulin Sensitivity and Insulin Secretion in the Progression From Normal Glucose Tolerance to Impaired Fasting Glycemia and Impaired Glucose Tolerance: The Inter99 Study. <i>Diabetes Care</i> , 2009, 32, 439-444.	4.3	126
730	Association of Type 2 Diabetes Candidate Polymorphisms in <i>KCNQ1</i> With Incretin and Insulin Secretion. <i>Diabetes</i> , 2009, 58, 1715-1720.	0.3	105
731	The Relationship between Glucagon-Like Peptide 2 and Feeding Intolerance in Preterm Infants. <i>Journal of Tropical Pediatrics</i> , 2009, 55, 276-277.	0.7	4
732	Preserved Inhibitory Potency of GLP-1 on Glucagon Secretion in Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4679-4687.	1.8	89
733	Hyperglycemia Acutely Lowers the Postprandial Excursions of Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1379-1385.	1.8	51
734	Impaired Glucose-Induced Glucagon Suppression after Partial Pancreatectomy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2857-2863.	1.8	27
735	Differential effects of protein quality on postprandial lipemia in response to a fat-rich meal in type 2 diabetes: comparison of whey, casein, gluten, and cod protein. <i>American Journal of Clinical Nutrition</i> , 2009, 90, 41-48.	2.2	122
736	$K_{ATP}$ Channel Closure Ameliorates the Impaired Insulinotropic Effect of Glucose-Dependent Insulinotropic Polypeptide in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 603-608.	1.8	48
737	Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 297, E532-E537.	1.8	74
738	Colonic GLP-2 is not Sufficient to Promote Jejunal Adaptation in a PN-Dependent Rat Model of Human Short Bowel Syndrome. <i>Journal of Parenteral and Enteral Nutrition</i> , 2009, 33, 629-639.	1.3	17

#	ARTICLE	IF	CITATIONS
739	Cognitive performance, symptoms and counter-regulation during hypoglycaemia in patients with type 1 diabetes and high or low renin-angiotensin system activity. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2009, 10, 216-229.	1.0	10
740	Preliminary report: genetic variation within the GPC6R1 gene is not associated with metabolic traits in white subjects at an increased risk for type 2 diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 1809-1811.	1.5	18
741	Changes of cognition and regional cerebral activity during acute hypoglycemia in normal subjects: A H <sub>2</sub> <sup>15</sup> O positron emission tomographic study. <i>Journal of Neuroscience Research</i> , 2009, 87, 1922-1928.	1.3	18
742	Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. <i>Advances in Therapy</i> , 2009, 26, 488-499.	1.3	66
743	No increased risk of hypoglycaemic episodes during 48h of subcutaneous glucagon-like peptide-1 administration in fasting healthy subjects. <i>Clinical Endocrinology</i> , 2009, 71, 500-506.	1.2	26
744	Serum Bile Acids Are Higher in Humans With Prior Gastric Bypass: Potential Contribution to Improved Glucose and Lipid Metabolism. <i>Obesity</i> , 2009, 17, 1671-1677.	1.5	501
745	Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. <i>American Journal of Clinical Nutrition</i> , 2009, 89, 106-113.	2.2	201
746	GLP-1 receptor agonists: Targeting both hyperglycaemia and disease processes in diabetes. <i>Diabetes Research and Clinical Practice</i> , 2009, 85, 1-3.	1.1	26
747	Four-month treatment with GLP-2 significantly increases hip BMD. <i>Bone</i> , 2009, 45, 833-842.	1.4	144
748	Effect of viscosity on appetite and gastro-intestinal hormones. <i>Physiology and Behavior</i> , 2009, 97, 68-75.	1.0	73
749	Temporal Changes in the Intestinal Growth Promoting Effects of Glucagon-Like Peptide 2 Following Intestinal Resection. <i>Journal of Surgical Research</i> , 2009, 152, 271-280.	0.8	29
750	The incretin system and its role in type 2 diabetes mellitus. <i>Molecular and Cellular Endocrinology</i> , 2009, 297, 127-136.	1.6	447
751	Immunoassays for the incretin hormones GIP and GLP-1. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 425-432.	2.2	55
752	The spectrum of antidiabetic actions of GLP-1 in patients with diabetes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 453-462.	2.2	21
753	Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 586-593.	1.5	44
754	Glucagon and Glucagon-Like Peptides 1 and 2. <i>Results and Problems in Cell Differentiation</i> , 2009, 50, 221-234.	0.2	37
755	Whey protein potentiates the intestinotrophic action of glucagon-like peptide-2 in parenterally fed rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2009, 297, R1554-R1562.	0.9	14
756	Glucagon-like peptide-2 increases mesenteric blood flow in humans. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 314-319.	0.6	104

#	ARTICLE	IF	CITATIONS
757	Gut Transit Is Associated With Gastrointestinal Symptoms and Gut Hormone Profile in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 346-352.	2.4	57
758	The effect of a high-MUFA, low-glycaemic index diet and a low-fat diet on appetite and glucose metabolism during a 6-month weight maintenance period. <i>British Journal of Nutrition</i> , 2009, 101, 1846-1858.	1.2	67
759	The effects of dietary fibre type on satiety-related hormones and voluntary food intake in dogs. <i>British Journal of Nutrition</i> , 2009, 102, 318-325.	1.2	72
760	Comparative effect of orally administered sodium butyrate before or after weaning on growth and several indices of gastrointestinal biology of piglets. <i>British Journal of Nutrition</i> , 2009, 102, 1285-1296.	1.2	89
761	G Protein-Coupled Receptor 39 Deficiency Is Associated with Pancreatic Islet Dysfunction. <i>Endocrinology</i> , 2009, 150, 2577-2585.	1.4	82
762	Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G482-G489.	1.6	25
763	Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists. <i>Current Diabetes Reviews</i> , 2009, 5, 266-275.	0.6	49
764	Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. <i>IDrugs: the Investigational Drugs Journal</i> , 2009, 12, 503-13.	0.7	26
765	Intestinal Permeability and Glucagon-like peptide-2 in Children with Autism: A Controlled Pilot Study. <i>Journal of Autism and Developmental Disorders</i> , 2008, 38, 1066-1071.	1.7	43
766	GLP-1: physiological effects and potential therapeutic applications. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 994-1003.	2.2	73
767	The physiology and pharmacology of incretins in type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 14-21.	2.2	23
768	Effects of Intravenous Glucagon-Like Peptide-1 on Glucose Control and Hemodynamics After Coronary Artery Bypass Surgery in Patients With Type 2 Diabetes. <i>American Journal of Cardiology</i> , 2008, 102, 646-647.	0.7	53
769	The effects of variations in dose and method of administration on glucagon like peptide-2 activity in the rat. <i>European Journal of Pharmacology</i> , 2008, 596, 138-145.	1.7	23
770	Glucagon-like peptide-1, glucose homeostasis and diabetes. <i>Trends in Molecular Medicine</i> , 2008, 14, 161-168.	3.5	152
771	Porcine glucagon-like peptide-2: Structure, signaling, metabolism and effects. <i>Regulatory Peptides</i> , 2008, 146, 310-320.	1.9	26
772	Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 1304-1310.	0.6	39
773	Plasma glucagon-like peptide 1 and peptide YY levels are not altered in symptomatic fructose-sorbitol malabsorption. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 1212-1218.	0.6	4
774	Functional Ontogeny of the Proglucagon-Derived Peptide Axis in the Premature Human Neonate. <i>Pediatrics</i> , 2008, 121, e180-e186.	1.0	32

#	ARTICLE	IF	CITATIONS
775	Acute Effects of Ghrelin Administration on Glucose and Lipid Metabolism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 438-444.	1.8	79
776	Exogenous Glucagon-Like Peptide-2 (GLP-2) Augments GLP-2 Receptor mRNA and Maintains Proglucagon mRNA Levels in Resected Rats. <i>Journal of Parenteral and Enteral Nutrition</i> , 2008, 32, 254-265.	1.3	41
777	Angiotensin-converting enzyme activity and cognitive impairment during hypoglycaemia in healthy humans. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2008, 9, 37-48.	1.0	14
778	Measurements of Islet Function and Glucose Metabolism with the Dipeptidyl Peptidase 4 Inhibitor Vildagliptin in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 459-464.	1.8	113
779	Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients. <i>Diabetes</i> , 2008, 57, 1340-1348.	0.3	353
780	Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans. <i>Diabetes</i> , 2008, 57, 325-331.	0.3	39
781	Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance. <i>Diabetes</i> , 2008, 57, 678-687.	0.3	307
782	Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose Tolerance. <i>Diabetes Care</i> , 2008, 31, 30-35.	4.3	147
783	Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-1 responses in rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2008, 295, R1794-R1802.	0.9	29
784	Orlistat Inhibition of Intestinal Lipase Acutely Increases Appetite and Attenuates Postprandial Glucagon-Like Peptide-1-(7-36)-Amide-1, Cholecystokinin, and Peptide YY Concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3995-3998.	1.8	77
785	Pharmacology of GLP-1-based therapies. <i>British Journal of Diabetes and Vascular Disease</i> , 2008, 8, S10-S18.	0.6	6
786	The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves $\beta$ -Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting Glucose. <i>Diabetes Care</i> , 2008, 31, 108-113.	4.3	126
787	Insulin-like growth factor I and glucagon-like peptide-2 responses to fasting followed by controlled or ad libitum refeeding in rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2008, 294, R1175-R1184.	0.9	46
788	Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 929-937.	0.6	32
789	GLP-2 Administration Results in Increased Proliferation but Paradoxically an Adverse Outcome in a Juvenile Piglet Model of Short Bowel Syndrome. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2008, 46, 20-28.	0.9	38
790	Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2008, 11, 491-499.	1.3	85
791	The effect of salatriam, a low-calorie modified triacylglycerol, on appetite and energy intake. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 1163-1169.	2.2	22
792	Comparison of the effects on insulin resistance and glucose tolerance of 6-mo high-monounsaturated-fat, low-fat, and control diets. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 855-862.	2.2	102

#	ARTICLE	IF	CITATIONS
793	Including Indigestible Carbohydrates in the Evening Meal of Healthy Subjects Improves Glucose Tolerance, Lowers Inflammatory Markers, and Increases Satiety after a Subsequent Standardized Breakfast. <i>Journal of Nutrition</i> , 2008, 138, 732-739.	1.3	243
794	Meal-induced compositional changes in blood and saliva in persons with bulimia nervosa. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 12-22.	2.2	16
795	DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. <i>Frontiers in Bioscience - Landmark</i> , 2008, 13, 1780.	3.0	67
796	Glucagon-like Peptides and Insulin Sensitivity. , 2008, , 233-254.		0
797	Coming of Age for the Incretins. , 2008, , 269-290.		0
798	Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility. <i>IDrugs: the Investigational Drugs Journal</i> , 2008, 11, 497-501.	0.7	6
799	Sulfonylurea Compounds Uncouple the Glucose Dependence of the Insulinotropic Effect of Glucagon-Like Peptide 1. <i>Diabetes</i> , 2007, 56, 438-443.	0.3	105
800	Glucagon-like peptide 2 has limited efficacy to increase nutrient absorption in fetal and preterm pigs. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2007, 293, R2179-R2184.	0.9	17
801	The Intestinotrophic Peptide, GLP-2, Counteracts Intestinal Atrophy in Mice Induced by the Epidermal Growth Factor Receptor Inhibitor, Gefitinib. <i>Clinical Cancer Research</i> , 2007, 13, 5170-5175.	3.2	35
802	Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, G288-G295.	1.6	40
803	Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E849-E856.	1.8	65
804	Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E604-E609.	1.8	87
805	Glucagon-Like Peptide-2 in Umbilical Cord Blood from Mature Infants. <i>Neonatology</i> , 2007, 91, 49-53.	0.9	2
806	Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 814-820.	0.6	37
807	The antagonistic metabolite of GLP-1, GLP-1 (9-36)amide, does not influence gastric emptying and hunger sensations in man. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 28-33.	0.6	4
808	Meal-Stimulated Glucagon Release Is Associated with Postprandial Blood Glucose Level and Does Not Interfere with Glycemic Control in Children and Adolescents with New-Onset Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2910-2916.	1.8	38
809	GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E1746-E1755.	1.8	211
810	Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, G211-G221.	1.6	149

#	ARTICLE	IF	CITATIONS
811	New Horizons in Diabetes Therapy. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2007, 7, 49-55.	0.5	3
812	The Dipeptidyl Peptidase IV Inhibitor Vildagliptin Suppresses Endogenous Glucose Production and Enhances Islet Function after Single-Dose Administration in Type 2 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1249-1255.	1.8	219
813	Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes. European Journal of Endocrinology, 2007, 156, 663-671.	1.9	55
814	Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E324-E330.	1.8	92
815	Effect of dairy calcium or supplementary calcium intake on postprandial fat metabolism, appetite, and subsequent energy intake. American Journal of Clinical Nutrition, 2007, 85, 678-687.	2.2	168
816	Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT. Journal of Clinical Pharmacology, 2007, 47, 633-641.	1.0	87
817	Metabolism of glucagon-like peptide-2 in pigs: Role of dipeptidyl peptidase IV. Regulatory Peptides, 2007, 138, 126-132.	1.9	18
818	Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion. Regulatory Peptides, 2007, 143, 64-68.	1.9	70
819	The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. Regulatory Peptides, 2007, 144, 123-130.	1.9	55
820	Disassociation of bone resorption and formation by GLP-2. Bone, 2007, 40, 723-729.	1.4	106
821	GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion. Molecular and Cellular Endocrinology, 2007, 276, 18-23.	1.6	86
822	The Physiology of Glucagon-like Peptide 1. Physiological Reviews, 2007, 87, 1409-1439.	13.1	2,504
823	Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus. Gynecological Endocrinology, 2007, 23, 58-62.	0.7	32
824	Gastrointestinal function and metabolic control after construction of an orthotopic ileal neobladder in bladder cancer. Scandinavian Journal of Urology and Nephrology, 2007, 41, 14-19.	1.4	14
825	Small-molecule agonists for the glucagon-like peptide 1 receptor. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 937-942.	3.3	204
826	Effects of PYY1 and PYY3 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E1062-E1068.	1.8	192
827	Reduced Incretin Effect in Type 2 Diabetes. Diabetes, 2007, 56, 1951-1959.	0.3	297
828	The Dipeptidyl Peptidase 4 Inhibitor Vildagliptin Does Not Accentuate Glibenclamide-Induced Hypoglycemia but Reduces Glucose-Induced Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide Secretion. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4165-4171.	1.8	105

#	ARTICLE	IF	CITATIONS
829	Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. <i>Surgery for Obesity and Related Diseases</i> , 2007, 3, 597-601.	1.0	311
830	Pharmacokinetics and Pharmacodynamics of Vildagliptin in Patients with Type 2 Diabetes Mellitus. <i>Clinical Pharmacokinetics</i> , 2007, 46, 577-588.	1.6	85
831	Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. <i>American Journal of Clinical Nutrition</i> , 2007, 85, 996-1004.	2.2	314
832	Cecal Infusion of Butyrate Increases Intestinal Cell Proliferation in Piglets. <i>Journal of Nutrition</i> , 2007, 137, 916-922.	1.3	97
833	Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 5472-5478.	1.0	56
834	Glucagon-Like Peptide 2 Stimulates Glucagon Secretion, Enhances Lipid Absorption, and Inhibits Gastric Acid Secretion in Humans. <i>Gastroenterology</i> , 2006, 130, 44-54.	0.6	218
835	GLP-2 Receptor Localizes to Enteric Neurons and Endocrine Cells Expressing Vasoactive Peptides and Mediates Increased Blood Flow. <i>Gastroenterology</i> , 2006, 130, 150-164.	0.6	214
836	Diet- and Colonization-Dependent Intestinal Dysfunction Predisposes to Necrotizing Enterocolitis in Preterm Pigs. <i>Gastroenterology</i> , 2006, 130, 1776-1792.	0.6	249
837	Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4612-4619.	1.8	464
838	Switching from Insulin to Oral Sulfonylureas in Patients with Diabetes Due to Kir6.2 Mutations. <i>New England Journal of Medicine</i> , 2006, 355, 467-477.	13.9	878
839	Dipeptidyl peptidase IV inhibitors: A promising new therapeutic approach for the management of type 2 diabetes. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 831-844.	1.2	99
840	The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. <i>Regulatory Peptides</i> , 2006, 137, 168-172.	1.9	52
841	Glucagon-like peptide 2 inhibits ghrelin secretion in humans. <i>Regulatory Peptides</i> , 2006, 137, 173-178.	1.9	15
842	The Rate of Intestinal Glucose Absorption Is Correlated with Plasma Glucose-Dependent Insulinotropic Polypeptide Concentrations in Healthy Men. <i>Journal of Nutrition</i> , 2006, 136, 1511-1516.	1.3	91
843	Synergistic effect of supplemental enteral nutrients and exogenous glucagon-like peptide 2 on intestinal adaptation in a rat model of short bowel syndrome. <i>American Journal of Clinical Nutrition</i> , 2006, 84, 1142-1150.	2.2	43
844	Effect of a high-protein breakfast on the postprandial ghrelin response. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 211-220.	2.2	181
845	Glycemic and insulinemic responses as determinants of appetite in humans. <i>American Journal of Clinical Nutrition</i> , 2006, 84, 1365-1373.	2.2	62
846	Wheat-fibre-induced changes of postprandial peptide YY and ghrelin responses are not associated with acute alterations of satiety. <i>British Journal of Nutrition</i> , 2006, 96, 795-798.	1.2	102



#	ARTICLE	IF	CITATIONS
847	Vagal afferents are essential for maximal resection-induced intestinal adaptive growth in orally fed rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2006, 291, R1256-R1264.	0.9	8
848	GIP-(3â€“42) does not antagonize insulinotropic effects of GIP at physiological concentrations. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 291, E468-E475.	1.8	54
849	Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 667-672.	0.6	38
850	Inhibition of human pancreatic and biliary output but not intestinal motility by physiological intraileal lipid loads. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G704-G709.	1.6	34
851	The glucagon-like peptide-1 metabolite GLP-1-(9â€“36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 290, E1118-E1123.	1.8	90
852	Effects of gastric emptying on the postprandial ghrelin response. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 290, E389-E395.	1.8	42
853	Impact of incretin hormones on Î²-cell function in subjects with normal or impaired glucose tolerance. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 291, E1144-E1150.	1.8	76
854	Immunoneutralization of Endogenous Glucagon Reduces Hepatic Glucose Output and Improves Long-Term Glycemic Control in Diabetic ob/ob Mice. <i>Diabetes</i> , 2006, 55, 2843-2848.	0.3	76
855	Feeding an Elemental Diet <i>vs</i> a Milk-Based Formula Does Not Decrease Intestinal Mucosal Growth in Infant Pigs. <i>Journal of Parenteral and Enteral Nutrition</i> , 2006, 30, 32-39.	1.3	15
856	Prohormone Convertase 1/3 Is Essential for Processing of the Glucose-dependent Insulinotropic Polypeptide Precursor. <i>Journal of Biological Chemistry</i> , 2006, 281, 11050-11057.	1.6	92
857	Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls. <i>World Journal of Gastroenterology</i> , 2006, 12, 1874.	1.4	8
858	Glucagonlike Peptides 1 and 2, Enteroglucagon, Glicentin, and Oxyntomodulin. , 2006, , 1057-1064.		0
859	Synergistic effect of supplemental enteral nutrients (SEN) and glucagon-like peptide-2 (GLP-2) in intestinal adaptation in a rat model of human short bowel syndrome (SBS). <i>FASEB Journal</i> , 2006, 20, .	0.2	0
860	Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 207-212.	0.8	48
861	Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. <i>American Journal of Clinical Nutrition</i> , 2005, 82, 69-75.	2.2	282
862	Glucagon-like peptide-1: physiology and therapeutic potential. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2005, 12, 56-62.	0.6	26
863	Enteral Feeding Without Pancreatic Stimulation. <i>Pancreas</i> , 2005, 31, 353-359.	0.5	83
864	The use of glycaemic index tables to predict glycaemic index of breakfast meals. <i>British Journal of Nutrition</i> , 2005, 94, 135-136.	1.2	6

#	ARTICLE	IF	CITATIONS
865	Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. <i>American Journal of Clinical Nutrition</i> , 2005, 82, 69-75.	2.2	274
866	Distinct Effects of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 on Insulin Secretion and Gut Motility. <i>Diabetes</i> , 2005, 54, 1056-1063.	0.3	103
867	Glucagon-Like Peptide 2 Dose-Dependently Activates Intestinal Cell Survival and Proliferation in Neonatal Piglets. <i>Endocrinology</i> , 2005, 146, 22-32.	1.4	135
868	Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic $\beta$ -cells. <i>European Journal of Endocrinology</i> , 2005, 152, 103-112.	1.9	32
869	Erythromycin Antagonizes the Deceleration of Gastric Emptying by Glucagon-Like Peptide 1 and Unmasks Its Insulinotropic Effect in Healthy Subjects. <i>Diabetes</i> , 2005, 54, 2212-2218.	0.3	113
870	Normal Secretion and Action of the Gut Incretin Hormones Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Young Men with Low Birth Weight. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4912-4919.	1.8	31
871	Evidence of an Association Between the Arg72 Allele of the Peptide YY and Increased Risk of Type 2 Diabetes. <i>Diabetes</i> , 2005, 54, 2261-2265.	0.3	33
872	GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. <i>Regulatory Peptides</i> , 2005, 124, 105-112.	1.9	179
873	Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. <i>Regulatory Peptides</i> , 2005, 128, 97-107.	1.9	90
874	Young, low-birth-weight men are not more susceptible to the diabetogenic effects of a prolonged free fatty acid exposure than matched controls. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 1398-1406.	1.5	3
875	Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5991-5997.	1.8	274
876	Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of $\beta$ -cells. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 287, E677-E685.	1.8	23
877	Onset of Small Intestinal Atrophy Is Associated with Reduced Intestinal Blood Flow in TPN-Fed Neonatal Piglets. <i>Journal of Nutrition</i> , 2004, 134, 1467-1474.	1.3	105
878	GLP-2 Levels in Infants With Intestinal Dysfunction. <i>Pediatric Research</i> , 2004, 56, 371-376.	1.1	67
879	Depletion of mucosal substance P in acute otitis media. <i>Acta Oto-Laryngologica</i> , 2004, 124, 794-797.	0.3	2
880	Impaired Intestinal Proglucagon Processing in Mice Lacking Prohormone Convertase 1. <i>Endocrinology</i> , 2004, 145, 1349-1355.	1.4	96
881	Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 287, E199-E206.	1.8	518
882	Stimulation of Insulin Secretion by Intravenous Bolus Injection and Continuous Infusion of Gastric Inhibitory Polypeptide in Patients With Type 2 Diabetes and Healthy Control Subjects. <i>Diabetes</i> , 2004, 53, S220-S224.	0.3	73

#	ARTICLE	IF	CITATIONS
883	The Incretin Approach for Diabetes Treatment: Modulation of Islet Hormone Release by GLP-1 Agonism. <i>Diabetes</i> , 2004, 53, S197-S204.	0.3	86
884	Additive Effects of Glucagon-Like Peptide 1 and Pioglitazone in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 1910-1914.	4.3	35
885	Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects. <i>Diabetes</i> , 2004, 53, 654-662.	0.3	277
886	Supplementation of total parenteral nutrition with butyrate acutely increases structural aspects of intestinal adaptation after an 80% jejunoileal resection in neonatal piglets. <i>Journal of Parenteral and Enteral Nutrition</i> , 2004, 28, 210-222.	1.3	157
887	Neural regulation of glucagon-like peptide-1 secretion in pigs. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 287, E939-E947.	1.8	85
888	Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 287, E431-E438.	1.8	33
889	Milrinone efficiently potentiates insulin secretion induced by orally but not intravenously administered glucose in C57BL6J mice. <i>European Journal of Pharmacology</i> , 2004, 498, 319-323.	1.7	10
890	Plasma GLP-2 Levels and Intestinal Markers in the Juvenile Pig During Intestinal Adaptation: Effects of Different Diet Regimens. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1688-1695.	1.1	33
891	Gastric emptying, gastric secretion and enterogastrone response after administration of milk proteins or their peptide hydrolysates in humans. <i>European Journal of Nutrition</i> , 2004, 43, 127-139.	1.8	246
892	Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 287, E1209-E1215.	1.8	583
893	Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV Inhibitors. <i>Diabetes</i> , 2004, 53, 1326-1335.	0.3	283
894	Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1091-1102.	1.9	176
895	Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. <i>Expert Opinion on Emerging Drugs</i> , 2004, 9, 155-166.	1.0	78
896	Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. <i>Current Opinion in Pharmacology</i> , 2004, 4, 589-596.	1.7	108
897	Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. <i>Bone</i> , 2004, 34, 140-147.	1.4	103
898	Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. <i>Regulatory Peptides</i> , 2004, 118, 11-18.	1.9	73
899	Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. <i>Regulatory Peptides</i> , 2004, 118, 89-97.	1.9	39
900	Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. <i>Regulatory Peptides</i> , 2004, 122, 209-217.	1.9	105

#	ARTICLE	IF	CITATIONS
901	Antihyperglycemic effects of stevioside in type 2 diabetic subjects. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 73-76.	1.5	274
902	Ethanol with a mixed meal decreases the incretin levels early postprandially and increases postprandial lipemia in type 2 diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 77-83.	1.5	24
903	Glycemia and insulinemia in healthy subjects after lactose-equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. <i>American Journal of Clinical Nutrition</i> , 2004, 80, 1246-1253.	2.2	390
904	Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. <i>Critical Care Medicine</i> , 2004, 32, 848-851.	0.4	87
905	The use of glycaemic index tables to predict glycaemic index of composite breakfast meals. <i>British Journal of Nutrition</i> , 2004, 91, 979-989.	1.2	156
906	Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 286, E621-E625.	1.8	117
907	Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. <i>Expert Opinion on Emerging Drugs</i> , 2004, 9, 155-66.	1.0	35
908	Differential Postprandial Lipoprotein Responses in Type 2 Diabetic Men with and without Clinical Evidence of a Former Myocardial Infarction. <i>Review of Diabetic Studies</i> , 2004, 1, 175-175.	0.5	26
909	Enteroglucagon. , 2004, , 709-715.		0
910	Role of Gastrointestinal Hormones in Postprandial Reduction of Bone Resorption. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 2180-2189.	3.1	272
911	GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1 1This work is a publication of the USDA/ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas.. <i>Gastroenterology</i> , 2003, 125, 136-147.	0.6	165
912	Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease. <i>Gastroenterology</i> , 2003, 124, 894-902.	0.6	205
913	Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2719-2725.	1.8	315
914	Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 1579-1585.	1.5	43
915	The reduction in hepatic insulin clearance after oral glucose is not mediated by Gastric inhibitory polypeptide (GIP). <i>Regulatory Peptides</i> , 2003, 113, 95-100.	1.9	18
916	Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. <i>Regulatory Peptides</i> , 2003, 114, 115-121.	1.9	360
917	GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. <i>Regulatory Peptides</i> , 2003, 114, 189-196.	1.9	284
918	Circulating leptin and thyroid dysfunction. <i>European Journal of Endocrinology</i> , 2003, 149, 257-271.	1.9	138

#	ARTICLE	IF	CITATIONS
919	Characterization of GLP-1 Effects on $\beta$ -Cell Function After Meal Ingestion in Humans. <i>Diabetes Care</i> , 2003, 26, 2860-2864.	4.3	71
920	The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion: Effects on $\beta$ -Cell Sensitivity in Type 2 and Nondiabetic Subjects. <i>Diabetes</i> , 2003, 52, 380-386.	0.3	513
921	Effects of Free Fatty Acids Per Se on Glucose Production, Gluconeogenesis, and Glycogenolysis. <i>Diabetes</i> , 2003, 52, 260-267.	0.3	97
922	Functional and Immunohistochemical Evaluation of Porcine Neonatal Islet-Like Cell Clusters. <i>Cell Transplantation</i> , 2003, 12, 13-25.	1.2	15
923	Insulin Secretion and Cellular Glucose Metabolism after Prolonged Low-Grade Intralipid Infusion in Young Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2775-2783.	1.8	39
924	No Hypoglycemia After Subcutaneous Administration of Glucagon-Like Peptide-1 in Lean Type 2 Diabetic Patients and in Patients With Diabetes Secondary to Chronic Pancreatitis. <i>Diabetes Care</i> , 2003, 26, 2581-2587.	4.3	39
925	Role of luminal nutrients and endogenous GLP-2 in intestinal adaptation to mid-small bowel resection. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 284, G670-G682.	1.6	73
926	Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes. <i>American Journal of Clinical Nutrition</i> , 2003, 77, 605-611.	2.2	178
927	Structural differences between rye and wheat breads but not total fiber content may explain the lower postprandial insulin response to rye bread. <i>American Journal of Clinical Nutrition</i> , 2003, 78, 957-964.	2.2	173
928	Meals with similar energy densities but rich in protein, fat, carbohydrate, or alcohol have different effects on energy expenditure and substrate metabolism but not on appetite and energy intake. <i>American Journal of Clinical Nutrition</i> , 2003, 77, 91-100.	2.2	287
929	Introduction of Enteral Food Increases Plasma GLP-2 and Decreases GLP-2 Receptor mRNA Abundance during Pig Development. <i>Journal of Nutrition</i> , 2003, 133, 1781-1786.	1.3	61
930	Differential regional metabolism of glucagon in anesthetized pigs. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2003, 285, E552-E560.	1.8	32
931	Neutral Endopeptidase 24.11 and Dipeptidyl Peptidase IV are Both Involved in Regulating the Metabolic Stability of Glucagon-like Peptide-1 in vivo. , 2003, 524, 303-312.		17
932	Implementation of GLP-1 Based Therapy of Type 2 Diabetes Mellitus Using DPP-IV Inhibitors. , 2003, 524, 263-279.		31
933	Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. <i>Journal of Clinical Investigation</i> , 2003, 112, 1550-1560.	3.9	140
934	Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. <i>Journal of Clinical Investigation</i> , 2003, 112, 1550-1560.	3.9	276
935	Abnormal release of incretins and cortisol after oral glucose in subjects with insulin-resistant myotonic dystrophy. <i>European Journal of Endocrinology</i> , 2002, 146, 397-405.	1.9	11
936	Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1239-1246.	1.8	515

#	ARTICLE	IF	CITATIONS
937	Early Differential Defects of Insulin Secretion and Action in 19-Year-Old Caucasian Men Who Had Low Birth Weight. <i>Diabetes</i> , 2002, 51, 1271-1280.	0.3	172
938	Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10293-10298.	3.3	310
939	Gliclazide Directly Inhibits Arginine-Induced Glucagon Release. <i>Diabetes</i> , 2002, 51, S381-S384.	0.3	17
940	GLP-1-(9â€“36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002, 282, E873-E879.	1.8	85
941	Postprandial glucose, insulin, and incretin responses to grain products in healthy subjects. <i>American Journal of Clinical Nutrition</i> , 2002, 75, 254-262.	2.2	246
942	Gastric Inhibitory Polypeptide Analogues. <i>BioDrugs</i> , 2002, 16, 175-181.	2.2	21
943	Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and Î²-cell function in type 2 diabetes: a parallel-group study. <i>Lancet, The</i> , 2002, 359, 824-830.	6.3	1,207
944	Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective. <i>Biochemical and Biophysical Research Communications</i> , 2002, 294, 1-4.	1.0	54
945	The truncated metabolite GLP-2 (3â€“33) interacts with the GLP-2 receptor as a partial agonist. <i>Regulatory Peptides</i> , 2002, 103, 9-15.	1.9	73
946	Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats. <i>Regulatory Peptides</i> , 2002, 105, 173-179.	1.9	59
947	GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat. <i>Regulatory Peptides</i> , 2002, 107, 129-135.	1.9	41
948	The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. <i>Regulatory Peptides</i> , 2002, 110, 39-45.	1.9	59
949	Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. <i>Diabetes/Metabolism Research and Reviews</i> , 2002, 18, 430-441.	1.7	149
950	Inhibition of gastric inhibitory polypeptide signaling prevents obesity. <i>Nature Medicine</i> , 2002, 8, 738-742.	15.2	798
951	Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. <i>Gastroenterology</i> , 2001, 120, 806-815.	0.6	490
952	PACAP 1â€“38 as neurotransmitter in the porcine antrum. <i>Regulatory Peptides</i> , 2001, 101, 109-121.	1.9	25
953	Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3717-3723.	1.8	767
954	Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 281, G752-G763.	1.6	88

#	ARTICLE	IF	CITATIONS
955	Reference intervals for glucose, $\beta$ -cell polypeptides, and counterregulatory factors during prolonged fasting. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2001, 280, E50-E58.	1.8	72
956	Secretion of Trophic Gut Peptides Is Not Different in Bolus- and Continuously Fed Piglets. <i>Journal of Nutrition</i> , 2001, 131, 729-732.	1.3	31
957	Diurnal metabolic profiles after 14 d of an ad libitum high-starch, high-sucrose, or high-fat diet in normal-weight never-obese and postobese women. <i>American Journal of Clinical Nutrition</i> , 2001, 73, 177-189.	2.2	66
958	Intestinal growth adaptation and glucagon-like peptide 2 in rats with ileal-jejunal transposition or small bowel resection. <i>Digestive Diseases and Sciences</i> , 2001, 46, 379-388.	1.1	57
959	Leptin Levels Are Associated with Fat Oxidation and Dietary-Induced Weight Loss in Obesity. <i>Obesity</i> , 2001, 9, 452-461.	4.0	59
960	Assessment of Hepatic Insulin Action in Obese Type 2 Diabetic Patients. <i>Diabetes</i> , 2001, 50, 1363-1370.	0.3	68
961	Incretin hormones - an update. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2001, 61, 75-85.	0.6	4
962	Tachykinins in the Porcine Pancreas: Potent Exocrine and Endocrine Effects Via NK-1 Receptors. <i>Pancreas</i> , 2000, 20, 241-247.	0.5	27
963	1,5-Anhydro-d-fructose increases glucose tolerance by increasing glucagon-like peptide-1 and insulin in mice. <i>European Journal of Pharmacology</i> , 2000, 397, 219-225.	1.7	27
964	Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. <i>European Journal of Pharmacology</i> , 2000, 404, 239-245.	1.7	184
965	Minimal enteral nutrient requirements for intestinal growth in neonatal piglets: how much is enough?. <i>American Journal of Clinical Nutrition</i> , 2000, 71, 1603-1610.	2.2	210
966	Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2000, 278, E1010-E1018.	1.8	119
967	PACAP-(1-38) as neurotransmitter in the porcine adrenal glands. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2000, 279, E1413-E1425.	1.8	23
968	PACAP contributes to insulin secretion after gastric glucose gavage in mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2000, 279, R424-R432.	0.9	29
969	Degradation of Endogenous and Exogenous Gastric Inhibitory Polypeptide in Healthy and in Type 2 Diabetic Subjects as Revealed Using a New Assay for the Intact Peptide <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3575-3581.	1.8	344
970	Antidiabetogenic Action of Cholecystokinin-8 in Type 2 Diabetes*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1043-1048.	1.8	64
971	In Vivo and in Vitro Degradation of Glucagon-Like Peptide-2 in Humans <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2884-2888.	1.8	126
972	Gut hormones as pharmaceuticals. <i>Regulatory Peptides</i> , 2000, 93, 45-51.	1.9	48

#	ARTICLE	IF	CITATIONS
973	Potential targets for glucagon-like peptide 2 (GLP-2) in the rat: distribution and binding of i.v. injected 125I-GLP-2. <i>Peptides</i> , 2000, 21, 1511-1517.	1.2	33
974	Structure, measurement, and secretion of human glucagon-like peptide-2. <i>Peptides</i> , 2000, 21, 73-80.	1.2	196
975	GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1999, 277, R910-R916.	0.9	160
976	Proglucagon Processing Profile in Canine L Cells Expressing Endogenous Prohormone Convertase 1/3 and Prohormone Convertase 2. <i>Endocrinology</i> , 1999, 140, 4800-4808.	1.4	43
977	Treatment of Type 2 diabetes mellitus based on glucagon-like peptide-1. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 1409-1415.	1.9	6
978	Inhibition of Sham Feeding-Stimulated Human Gastric Acid Secretion by Glucagon-Like Peptide-2. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2513-2517.	1.8	146
979	Importance of colonic bacterial fermentation in short bowel patients: small intestinal malabsorption of easily digestible carbohydrate. <i>Digestive Diseases and Sciences</i> , 1999, 44, 1914-1923.	1.1	19
980	Tachykinins stimulate release of peptide hormones (glucagon-like peptide-1) and paracrine (somatostatin) and neurotransmitter (vasoactive intestinal polypeptide) from porcine ileum through NK-1 receptors. <i>Digestive Diseases and Sciences</i> , 1999, 44, 1273-1281.	1.1	10
981	Increased circulating leptin in alcoholic cirrhosis: Relation to release and disposal. <i>Hepatology</i> , 1999, 29, 1818-1824.	3.6	92
982	Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential. <i>Trends in Endocrinology and Metabolism</i> , 1999, 10, 229-235.	3.1	116
983	Inhibition of human gastric lipase by intraduodenal fat involves glucagon-like peptide-1 and cholecystokinin. <i>Regulatory Peptides</i> , 1999, 80, 101-106.	1.9	7
984	The hypothalamic satiety peptide CART is expressed in anorectic and non-anorectic pancreatic islet tumors and in the normal islet of Langerhans. <i>FEBS Letters</i> , 1999, 447, 139-143.	1.3	90
985	Glucagon-Like Peptide-1-(7-36)Amide Is Transformed to Glucagon-Like Peptide-1-(9-36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine. <i>Endocrinology</i> , 1999, 140, 5356-5363.	1.4	497
986	Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. <i>American Journal of Clinical Nutrition</i> , 1999, 69, 1135-1143.	2.2	270
987	The arcuate nucleus is pivotal in mediating the anorectic effects of centrally administered leptin. <i>NeuroReport</i> , 1999, 10, 1183-1187.	0.6	60
988	Glucagon-like Peptide-1, A Gastrointestinal Hormone with a Pharmaceutical Potential. <i>Current Medicinal Chemistry</i> , 1999, 6, 1005-1017.	1.2	57
989	Inhibition of human gastric lipase secretion by glucagon-like peptide-1. <i>Digestive Diseases and Sciences</i> , 1998, 43, 799-805.	1.1	31
990	Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. <i>Digestive Diseases and Sciences</i> , 1998, 43, 2284-2290.	1.1	100



#	ARTICLE	IF	CITATIONS
991	Importance of Small Bowel Peptides for the Improved Glucose Metabolism 20 Years after Jejunoileal Bypass for Obesity. Obesity Surgery, 1998, 8, 253-260.	1.1	131
992	On the Treatment of Diabetes Mellitus with Glucagon-like Peptide-1. Annals of the New York Academy of Sciences, 1998, 865, 336-343.	1.8	24
993	Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Archiv European Journal of Physiology, 1998, 435, 583-594.	1.3	227
994	The relationship between the serum leptin concentrations of thyrotoxic patients during treatment and their total fat mass is different from that of normal subjects. Clinical Endocrinology, 1998, 49, 589-595.	1.2	41
995	Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid) Tj ETQq1,1,0.784314 rgBT 1,9 51	1.9	51
996	Treatment of type 2 diabetes with glucagonlike peptide 1. Current Opinion in Endocrinology, Diabetes and Obesity, 1998, 5, 108-115.	0.6	4
997	Isolation and Molecular Characterization of Porcine Calcitonin Gene-Related Peptide (CGRP) and Its Endocrine Effects in the Porcine Pancreas. Pancreas, 1998, 16, 195-204.	0.5	15
998	Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. American Journal of Physiology - Renal Physiology, 1998, 275, G984-G992.	1.6	94
999	Effects of Glucagon-Like Peptide-1 on Islet Function and Insulin Sensitivity in Noninsulin-Dependent Diabetes Mellitus1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 473-478.	1.8	124
1000	Short Term Insulin Treatment Prevents the Diabetogenic Action of Streptozotocin in Rats<sup>1</sup>. Endocrinology, 1997, 138, 62-68.	1.4	66
1001	Posttranslational Processing of Proglucagon and Postsecretory Fate of Proglucagon Products. Frontiers in Diabetes, 1997, 13, 24-48.	0.4	8
1002	Use of Antagonists to Define Tachykininergic Control of Intestinal Motility in Pigs. Peptides, 1997, 18, 373-379.	1.2	11
1003	Tachykinins May Mediate Capsaicin-Induced, But Not Vagally Induced Motility in Porcine Antrum. Peptides, 1997, 18, 1511-1516.	1.2	14
1004	Effects of GLP-1 on Gastric Acid and Pancreatic Exocrine Secretion and on Gastrointestinal Motility. Frontiers in Diabetes, 1997, 13, 194-206.	0.4	0
1005	Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. American Journal of Physiology - Endocrinology and Metabolism, 1997, 273, E981-E988.	1.8	423
1006	Neuropeptides and Morphological Changes in Cisplatin-Induced Dorsal Root Ganglion Neuronopathy. Experimental Neurology, 1996, 138, 93-104.	2.0	73
1007	Effects of insulin on glucose turnover rates in vivo: Isotope dilution versus constant specific activity technique. Metabolism: Clinical and Experimental, 1996, 45, 82-91.	1.5	92
1008	Regulation of Motilin Release from Isolated Perfused Pig Duodenum. Digestion, 1996, 57, 341-348.	1.2	7

#	ARTICLE	IF	CITATIONS
1009	Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM) – evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. <i>European Journal of Endocrinology</i> , 1996, 135, 425-432.	1.9	146
1010	PACAP 1-27 and 1-38 in the Porcine Pancreas: Occurrence, Localization, and Effects. <i>Annals of the New York Academy of Sciences</i> , 1996, 805, 521-535.	1.8	9
1011	On the Effects of Glucagon-Like Peptide-1 on Blood Glucose Regulation in Normal and Diabetic Subjects. <i>Annals of the New York Academy of Sciences</i> , 1996, 805, 729-736.	1.8	16
1012	Comparison of sandwich enzyme-linked immunoadsorbent assay and radioimmunoassay for determination of exogenous glucagon-like peptide-1(7-36)amide in plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1995, 13, 841-850.	1.4	20
1013	Ileal release of glucagon-like peptide-1 (GLP-1). <i>Digestive Diseases and Sciences</i> , 1995, 40, 1074-1082.	1.1	199
1014	Human colon produces fully processed glucagon-like peptide-1 (7-36) amide. <i>FEBS Letters</i> , 1995, 372, 269-272.	1.3	21
1015	Histochemical, pharmacological, biochemical and chromatographic evidence that pituitary adenylyl cyclase activating peptide is involved in inhibitory neurotransmission in the taenia of the guinea-pig caecum. <i>Journal of the Autonomic Nervous System</i> , 1995, 50, 311-322.	1.9	67
1016	Sympathoadrenal Regulation of Adrenal Androstenedione Release. <i>Neuroendocrinology</i> , 1994, 59, 406-412.	1.2	30
1017	Exendin-4 and exendin-(9-39)NH <sub>2</sub> : agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH <sub>2</sub> . <i>European Journal of Pharmacology</i> , 1994, 269, 183-191.	2.7	54
1018	Peptide-evoked release of amylase from isolated acini of the rat parotid gland. <i>Regulatory Peptides</i> , 1994, 51, 237-254.	1.9	11
1019	Pigs produce only a single form of CGRP, part of which is processed to fragments. <i>Peptides</i> , 1994, 15, 89-94.	1.2	12
1020	6 Gut hormones and intestinal function. <i>Bailliere's Clinical Endocrinology and Metabolism</i> , 1994, 8, 137-164.	1.0	11
1021	Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. <i>Metabolism: Clinical and Experimental</i> , 1994, 43, 104-108.	1.5	176
1022	Glucagonlike peptide 1: A newly discovered gastrointestinal hormone. <i>Gastroenterology</i> , 1994, 107, 1848-1855.	0.6	245
1023	Secretion of Glucagon-Like Peptide-1 and Reactive Hypoglycemia after Partial Gastrectomy. <i>Digestion</i> , 1994, 55, 221-228.	1.2	56
1024	Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. <i>Digestive Diseases and Sciences</i> , 1993, 38, 665-673.	1.1	626
1025	Release of immunoreactive somatostatin, vasoactive intestinal polypeptide (VIP), and galanin during propulsive complexes in isolated pig ileum. <i>Peptides</i> , 1993, 14, 215-220.	1.2	17
1026	Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance. <i>European Journal of Endocrinology</i> , 1993, 128, 207-214.	1.9	97

#	ARTICLE	IF	CITATIONS
1027	Cerebrovascular changes following administration of gammaglobulins against substance P or calcitonin gene related peptide in monkey with subarachnoid haemorrhage. British Journal of Neurosurgery, 1993, 7, 507-518.	0.4	8
1028	Glucagon-Like Peptide 1: On Its Way to Clinical Application. Digestion, 1993, 54, 339-340.	1.2	8
1029	Antidiabetogenic Effect of Glucagon-like Peptide-1 (7â€³36)amide in Normal Subjects and Patients with Diabetes Mellitus. New England Journal of Medicine, 1992, 326, 1316-1322.	13.9	860
1030	Somatostatin Is an Essential Paracrine Link in Acid Inhibition of Gastrin Secretion. Digestion, 1992, 51, 95-102.	1.2	31
1031	Discussing the Role of Glucagonlike Peptide-I. Diabetes Care, 1992, 15, 1440-1441.	4.3	0
1032	Extrinsic control of the release of galanin and VIP from intrinsic nerves of isolated, perfused, porcine ileum. Regulatory Peptides, 1992, 38, 179-198.	1.9	17
1033	Nervous control of the release of substance P and neurokinin A from the isolated perfused porcine ileum. Journal of the Autonomic Nervous System, 1992, 38, 85-95.	1.9	27
1034	Somatostatinand Prosomatostatin Immunoreactive Nerve Fibers in the Bovine Pineal Gland. Neuroendocrinology, 1992, 56, 278-283.	1.2	13
1035	Oxidation/reduction explains heterogeneity of pancreatic somatostatin. FEBS Letters, 1991, 279, 237-239.	1.3	2
1036	Human galanin: Primary structure and indentification of two molecular forms. FEBS Letters, 1991, 283, 189-194.	1.3	109
1037	Substance P and neurokinin A are codistributed and colocalized in the porcine gastrointestinal tract. Peptides, 1991, 12, 963-973.	1.2	68
1038	Role of the Vasoactive Intestinal Peptide in a Neuroendocrine Regulation of the Adrenal Cortex. Neuroendocrinology, 1991, 54, 623-628.	1.2	56
1039	Nerve Fibers in the Rat Posterior Pituitary Lobe Contain Prosomatostatin (1â€³64). Neuroendocrinology, 1991, 54, 469-476.	1.2	7
1040	Neuropeptide Y (NPY) and vasoactive intestinal polypeptide (VIP), but not galanin, are autonomic cotransmitters in the porcine pancreas. International Journal of Gastrointestinal Cancer, 1991, 10, 133-41.	0.4	4
1041	Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Digestive Diseases and Sciences, 1991, 36, 1361-1370.	1.1	156
1042	Galanin and Galanin Extended at the N-Terminus with Seven and Nine Amino Acids Are Produced in and Secreted from the Porcine Adrenal Medulla in almost Equal Amounts*. Endocrinology, 1991, 129, 2693-2698.	1.4	32
1043	Differential effects of secretinâ€³fragments imply a dual mechanism of action for secretin. International Journal of Peptide and Protein Research, 1991, 37, 134-139.	0.1	8
1044	Pancreatic Spasmolytic Polypeptide, a Potential Growth Factor for the Intestine: Neural Control of Secretion. Digestion, 1990, 46, 226-231.	1.2	15

#	ARTICLE	IF	CITATIONS
1045	Somatostatin Inhibits Neurally Stimulated Pancreatic Secretion Indirectly. <i>Pancreas</i> , 1990, 5, 611-614.	0.5	6
1046	Galanin: Distribution and Effect on Contractile Activity and Release of Vasoactive Intestinal Polypeptide from the Isolated Perfused Porcine Ileum. <i>Digestion</i> , 1990, 47, 191-199.	1.2	14
1047	Effects of Splanchnic Nerve Stimulation on the Adrenal Cortex May Be Mediated by Chromaffin Cells in a Paracrine Manner. <i>Endocrinology</i> , 1990, 127, 900-906.	1.4	147
1048	Somatostatin and prosomatostatin in the retina of the rat: An immunohistochemical, in-situ hybridization, and chromatographic study. <i>Visual Neuroscience</i> , 1990, 5, 441-452.	0.5	31
1049	Immunocytochemical localization and identification of prosomatostatin gene products in medullary carcinoma of human thyroid gland. <i>Human Pathology</i> , 1990, 21, 820-830.	1.1	18
1050	Galanin in the porcine pancreas. <i>Regulatory Peptides</i> , 1990, 28, 161-176.	1.9	44
1051	Somatostatin release induced by gastrin-releasing peptide in man. Effect of proximal gastric vagotomy and cholinergic blockade. <i>Regulatory Peptides</i> , 1990, 29, 133-141.	1.9	3
1052	Occurrence, Distribution and Motor Effects of Galanin in the Porcine Lower Esophageal Sphincter. <i>Digestion</i> , 1989, 42, 151-157.	1.2	20
1053	Pancreastatin-Like Immunoreactivity and Insulin are Released in Parallel from the Perfused Porcine Pancreas. <i>Endocrinology</i> , 1989, 124, 2986-2990.	1.4	31
1054	Oxyntomodulin from distal gut. <i>Digestive Diseases and Sciences</i> , 1989, 34, 1411-1419.	1.1	111
1055	Release of PYY from pig intestinal mucosa; luminal and neural regulation. <i>Regulatory Peptides</i> , 1989, 26, 253-266.	1.9	45
1056	The Role of Gastrin-Releasing Peptide in Pancreatic Exocrine Secretion. <i>Annals of the New York Academy of Sciences</i> , 1988, 547, 234-241.	1.8	3
1057	Oxyntomodulin (glicentin-(33-69)); pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. <i>Regulatory Peptides</i> , 1988, 21, 151-166.	1.9	98
1058	Secretion uncouples glucose inhibition of glucagon-producing cells resulting in a simultaneous stimulation of both glucagon and insulin release. <i>Regulatory Peptides</i> , 1988, 23, 315-322.	1.9	5
1059	Role of gastrin-releasing peptide in pepsinogen secretion from the isolated perfused rat stomach. <i>Regulatory Peptides</i> , 1988, 23, 95-104.	1.9	4
1060	Early detection of response in small cell bronchogenic carcinoma by changes in serum concentrations of creatine kinase, neuron specific enolase, calcitonin, ACTH, serotonin and gastrin releasing peptide. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1988, 24, 1033-1038.	0.9	39
1061	Interleukin-1 potentiates glucose stimulated insulin release in the isolated perfused pancreas. <i>European Journal of Endocrinology</i> , 1988, 117, 302-306.	1.9	24
1062	Role of gastrin-releasing peptide in the neural control of pepsinogen secretion from the pig stomach. <i>Gastroenterology</i> , 1988, 95, 1216-1220.	0.6	24

#	ARTICLE	IF	CITATIONS
1063	The Gastric Acid Secretagogue Gastrin-Releasing Peptide and the Inhibitor Oxyntomodulin Do Not Exert Their Effect Directly on the Parietal Cell in the Rat. <i>Digestion</i> , 1988, 40, 144-151.	1.2	13
1064	Enteroglucagon. <i>Advances in Metabolic Disorders</i> , 1988, , 393-419.	0.3	5
1065	Heterogeneity of immunoreactive gastric inhibitory polypeptide in the plasma of newly diagnosed type 1 (insulin-dependent) diabetics. <i>European Journal of Endocrinology</i> , 1987, 114, 74-83.	1.9	6
1066	Corticotropin-Releasing Activity of Gastrin-Releasing Peptide in Normal Men*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1987, 65, 1291-1295.	1.8	11
1067	Gastrin-Releasing Peptide in the Porcine Pancreas. <i>Gastroenterology</i> , 1987, 92, 1153-1158.	0.6	50
1068	Does the Endocrine Secretion of the Pancreas Exert a Local Control of the Exocrine Secretion?. <i>Pancreas</i> , 1987, 2, 613-619.	0.5	18
1069	Localization in the gastrointestinal tract of immunoreactive prosomatostatin. <i>Regulatory Peptides</i> , 1987, 19, 183-195.	1.9	22
1070	The effect of gastrin-releasing peptide on the endocrine pancreas. <i>Regulatory Peptides</i> , 1987, 17, 269-276.	1.9	23
1071	Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1987, 47, 165-174.	0.6	86
1072	Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas*. <i>Endocrinology</i> , 1986, 119, 1467-1475.	1.4	455
1073	Autonomic nervous control of the endocrine secretion from the isolated, perfused pig pancreas. <i>Journal of the Autonomic Nervous System</i> , 1986, 17, 71-84.	1.9	53
1074	Regulatory peptides in the lower esophageal sphincter of man. <i>Regulatory Peptides</i> , 1985, 10, 167-178.	1.9	56
1075	The intestinal mucosa preferentially releases somatostatin-28 in pigs. <i>Regulatory Peptides</i> , 1985, 11, 251-262.	1.9	39
1076	Glicentin is present in the pig pancreas. <i>FEBS Letters</i> , 1985, 179, 1-6.	1.3	14
1077	Radioimmunoassay, pharmacokinetics, and neuronal release of gastrin-releasing peptide in anesthetized pigs. <i>Gastroenterology</i> , 1984, 87, 372-378.	0.6	71
1078	Gastrin-Releasing Peptide: Pharmacokinetics and Effects on Gastro-Entero-Pancreatic Hormones and Gastric Secretion In Normal Men*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1984, 59, 310-315.	1.8	71
1079	The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. <i>Regulatory Peptides</i> , 1984, 9, 35-46.	1.9	103
1080	Vasoactive intestinal polypeptide (VIP) in the pig pancreas: role of VIPergic nerves in control of fluid and bicarbonate secretion. <i>Regulatory Peptides</i> , 1984, 8, 245-259.	1.9	86

#	ARTICLE	IF	CITATIONS
1081	Glucagon—how to prove its role in amino acid metabolism. <i>European Journal of Clinical Investigation</i> , 1983, 13, 107-108.	1.7	8
1082	Somatostatin —28 circulates in human plasma. <i>Regulatory Peptides</i> , 1983, 6, 63-69.	1.9	35
1083	Stripping of endogenous ligands from antisera against glucagon. <i>Journal of Immunological Methods</i> , 1983, 58, 83-91.	0.6	5
1084	Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin—Current status. <i>Gastroenterology</i> , 1983, 84, 1602-1613.	0.6	110
1085	Nervous control of gastro-pancreatic somatostatin secretion in pigs. <i>Peptides</i> , 1981, 2, 215-221.	1.2	12
1086	Heterogeneity of somatostatin like immunoreactivity (SLI) in extracts of porcine, canine and human pancreas. <i>European Journal of Endocrinology</i> , 1981, 98, 564-572.	1.9	57
1087	Nervous control of pancreatic endocrine secretion in pigs. <i>Acta Physiologica Scandinavica</i> , 1981, 111, 1-7.	2.3	46
1088	Nervous control of pancreatic endocrine secretion in pigs. <i>Acta Physiologica Scandinavica</i> , 1981, 111, 9-14.	2.3	31
1089	Nervous control of pancreatic endocrine secretion in pigs. <i>Acta Physiologica Scandinavica</i> , 1981, 111, 15-22.	2.3	26
1090	Secretory effects of cholecystokinins on the isolated perfused porcine pancreas. <i>Acta Physiologica Scandinavica</i> , 1981, 111, 225-231.	2.3	41
1091	Nervous control of pancreatic endocrine secretion in pigs IV. The effect of somatostatin on the insulin and glucagon responses to electrical vagal stimulation and to intraarterial acetylcholine. <i>Acta Physiologica Scandinavica</i> , 1981, 113, 273-278.	2.3	4
1092	Nervous control of pancreatic endocrine secretion in pigs V. Influence of the sympathetic nervous system on the pancreatic secretion of insulin and glucagon, and on the insulin and glucagon response to vagal stimulation. <i>Acta Physiologica Scandinavica</i> , 1981, 113, 279-283.	2.3	25
1093	Oxygen supply, oxygen consumption, and endocrine and exocrine secretions of the isolated, perfused, porcine pancreas. <i>Acta Physiologica Scandinavica</i> , 1980, 109, 7-13.	2.3	39
1094	Simultaneous recording of the gastro-entero-pancreatic hormonal peptide response to food in man. <i>Metabolism: Clinical and Experimental</i> , 1980, 29, 777-779.	1.5	33
1095	Nervous control of pancreatic exocrine secretion in pigs. <i>Acta Physiologica Scandinavica</i> , 1979, 105, 33-51.	2.3	83
1096	The effect of gastrin on basal and aminoacid-stimulated insulin and glucagon secretion in man. <i>European Journal of Clinical Investigation</i> , 1978, 8, 5-9.	1.7	32
1097	Reflex adrenergic control of endocrine pancreas evoked by unloading of carotid baroreceptors in cats. <i>Acta Physiologica Scandinavica</i> , 1978, 104, 188-202.	2.3	42
1098	Inhibition of Gastric Acid Secretion in Man by Exogenous and Endogenous Pancreatic Glucagon. <i>Gastroenterology</i> , 1976, 70, 688-692.	0.6	66

#	ARTICLE	IF	CITATIONS
1099	Adrenocortical function after major gastric surgery. American Journal of Surgery, 1973, 126, 595-597.	0.9	0
1100	Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients. , 0, .		224
1101	The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection. Frontiers in Endocrinology, 0, 13, .	1.5	1
1102	Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in Beta Cell Function in Patients with Type 2 Diabetes. Diabetes, 0, , .	0.3	1